nrc20260331_10q.htm

0001437749-26-015083.txt : 20260506 0001437749-26-015083.hdr.sgml : 20260506 20260506114210 ACCESSION NUMBER: 0001437749-26-015083 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20260331 FILED AS OF DATE: 20260506 DATE AS OF CHANGE: 20260506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NRC HEALTH CENTRAL INDEX KEY: 0000070487 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 470634000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35929 FILM NUMBER: 26947002 BUSINESS ADDRESS: STREET 1: 1245 Q STREET CITY: LINCOLN STATE: NE ZIP: 68508 BUSINESS PHONE: 4024752525 MAIL ADDRESS: STREET 1: 1245 Q STREET CITY: LINCOLN STATE: NE ZIP: 68508 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL RESEARCH CORP DATE OF NAME CHANGE: 19970715 10-Q 1 nrc20260331_10q.htm FORM 10-Q nrc20260331_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended March 31, 2026

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from ________ to ________

Commission File Number 001-35929

NRC Health

(Exact name of Registrant as specified in its charter)

Delaware		47-0634000
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

	1245 Q Street, Lincoln, Nebraska 68508
	(Address of principal executive offices) (Zip Code)

	(402) 475-2525
	(Registrant’s telephone number, including area code)

	National Research Corporation
	(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $.001 par value	NRC	The NASDAQ stock market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

Common Stock, $.001 par value, outstanding as of April 30, 2026: 22,536,696

Table of Contents

NRC HEALTH

FORM 10-Q INDEX

For the Quarter Ended March 31, 2026

			Page No.

PART I.	FINANCIAL INFORMATION

	Item 1.	Financial Statements	3

		Condensed Consolidated Balance Sheets	3
		Condensed Consolidated Statements of Income	4
		Condensed Consolidated Statements of Shareholders’ Equity	5
		Condensed Consolidated Statements of Cash Flows	7
		Notes to Condensed Consolidated Financial Statements	9-7

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15-21

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22

	Item 4.	Controls and Procedures	22

PART II.	OTHER INFORMATION

	Item 1.	Legal Proceedings	22

	Item 1A.	Risk Factors	22

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23

	Item 5.	Other Information	23

	Item 6.	Exhibits	24

	Signatures		25

Table of Contents

Special Note Regarding Forward-Looking Statements

Certain matters discussed in this Quarterly Report on Form 10-Q are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can generally be identified as such because the context of the statement includes phrases such as NRC Health, formerly known as National Research Corporation (“the Company,” “we,” “our,” “us” or similar terms), “believes,” “expects,” “may,” “could,” “anticipates,” “estimates,” “plans,” “creates,” “intends,” or the use of words such as “would,” “will,” “may,” “could,” “goal,” “focus,” or “should,” or other words of similar import. Similarly, statements that describe our future plans, objectives or goals are also forward-looking statements. In this Quarterly Report on Form 10-Q, statements regarding the value and utility of, and market demand for, our service offerings, future opportunities for growth with respect to new and existing customers, our future ability to compete and the types of firms with which we will compete, future consolidation in the healthcare industry, future adequacy of our liquidity sources, future revenue sources, future revenue, expenses, and margins, future revenue estimates used to calculate total recurring contract value, the expected impact of economic factors, including interest rates and inflation, future capital expenditures, and the timing, amount, and sources of cash to fund such capital expenditures, future stock repurchases and dividends, the expected impact of pending claims and contingencies, the future outcome of uncertain tax positions, future non-cash charges related to executive equity awards, our future use of owned and leased real property, and the expected impact of global conflicts, among others, are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties which could cause actual results or outcomes to differ materially from those currently anticipated. Factors that could affect actual results or outcomes include, without limitation, the following factors:

●	The possibility of non-renewal of our customer service contracts, reductions in services purchased or prices, and failure to retain key customers;

●	Our ability to compete in our markets, which are highly competitive with new market entrants and subject to consolidation among existing competitors, and the possibility of increased price pressure and expenses;

●	The possibility that our solutions and technology do not perform as expected;

●	The possibility that our acquisitions and partnerships do not achieve the increased demand/profitability expected;

●	The likelihood that a pandemic will adversely affect our operations, sales, earnings, financial condition, and liquidity;

●	The likelihood that global conflicts or tariffs will adversely affect our operations, sales, earnings, financial condition, and liquidity;

●	The effects of an economic downturn;

●	The impact of consolidation in the healthcare industry;

●	The impact of federal healthcare and budget legislation, executive orders, cost-saving measures, and other regulatory changes;

●	Our ability to attract and retain key managers and other personnel;

●	The possibility that our intellectual property and other proprietary information technology could be copied or independently developed by our competitors;

●	Our ability to maintain effective internal controls;

●	The possibility for failures or deficiencies in our information technology platform;

●	The possibility that we or our third-party providers could be subject to cyber-attacks, security breaches, or computer viruses; and

●

The factors set forth under the caption “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K, as such section may be updated or supplemented by Part II, Item 1A of our subsequently filed Quarterly Reports on Form 10-Q (including this Report) and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission.

Shareholders, potential investors, and other readers are urged to consider these and other factors in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included are only made as of the date of this Quarterly Report on Form 10-Q and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as required by the federal securities laws.

Table of Contents

PART I – Financial Information

ITEM 1. Financial Statements

NRC HEALTH

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts and par value)

	March 31, 2026			December 31, 2025
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	2,547		$	4,139
Trade accounts receivable, less allowance for credit losses of $90 and $80, respectively		10,833			11,108
Prepaid expenses		5,662			3,914
Income taxes receivable		481			528
Other current assets		461			520
Total current assets		19,984			20,209

Property and equipment, net		40,305			40,474
Intangible assets, net		2,165			2,227
Goodwill		66,152			66,152
Deferred contract costs, net		3,123			2,498
Other noncurrent assets		2,830			3,318
Total assets	$	134,559		$	134,878
Liabilities and Shareholders’ Equity
Current liabilities:
Current portion of notes payable, net of unamortized debt issuance costs	$	4,015		$	4,014
Accounts payable		2,227			1,169
Accrued wages and bonuses		6,603			7,218
Accrued expenses		2,582			2,897
Dividends payable		3,606			3,625
Deferred revenue		17,192			16,201
Income taxes payable		1,768			550
Other current liabilities		477			946
Total current liabilities		38,470			36,620

Notes payable, net of current portion and unamortized debt issuance costs		74,017			75,021
Deferred income taxes		5,999			5,984
Other long-term liabilities		2,578			3,263
Total liabilities		121,064			120,888

Shareholders’ equity:
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued		-			-
Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,975,649 in 2026 and 31,966,504 in 2025, outstanding 22,536,696 in 2026 and 22,637,252 in 2025		32			32
Additional paid-in capital		185,627			183,880
Retained earnings (accumulated deficit)		(17,682	)		(17,298	)
Treasury stock, at cost; 9,438,953 and 9,329,252 Common shares in 2026 and 2025, respectively		(154,482	)		(152,624	)
Total shareholders’ equity		13,495			13,990
Total liabilities and shareholders’ equity	$	134,559		$	134,878

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NRC HEALTH

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except for per share amounts, unaudited)

	Three months ended March 31,
	2026			2025

Revenue	$	34,803		$	33,551

Operating expenses:
Direct		13,646			13,057
Selling, general, and administrative		13,419			10,356
Depreciation and amortization		2,169			1,542
Total operating expenses		29,234			24,955

Operating income		5,569			8,596

Other income (expense):
Interest income		35			19
Interest expense		(1,255	)		(899	)
Other, net		30			7

Total other expense		(1,190	)		(873	)

Income before income taxes		4,379			7,723

Provision for income taxes		1,157			1,936

Net income	$	3,222		$	5,787

Earnings per share of common stock:
Basic	$	0.14		$	0.25
Diluted	$	0.14		$	0.25

Weighted average shares and share equivalents outstanding:
Basic		21,799			22,972
Diluted		21,911			22,974

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NRC HEALTH

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands except share and per share amounts, unaudited)

	Common Stock		Additional Paid-in Capital		Retained Earnings (Deficit)			Treasury Stock			Total
Balances at December 31, 2025	$	32	$	183,880	$	(17,298	)	$	(152,624	)	$	13,990
Purchase of 109,701 shares treasury stock		-		-		-			(1,858	)		(1,858	)
Issuance of 9,145 shares of common stock for the exercise of stock options		-		139		-			-			139
Non-cash stock compensation expense		-		1,608		-			-			1,608
Dividends declared of $0.16 per share of common stock		-		-		(3,606	)		-			(3,606	)
Net income		-		-		3,222			-			3,222
Balances at March 31, 2026	$	32	$	185,627	$	(17,682	)	$	(154,482	)	$	13,495

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NRC HEALTH

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands except share and per share amounts, unaudited)

	Common Stock		Additional Paid-in Capital		Retained Earnings (Deficit)			Treasury Stock			Total
Balances at December 31, 2024	$	31	$	180,249	$	(17,064	)	$	(131,932	)	$	31,284
Purchase of 307,709 shares treasury stock		-		-		-			(4,967	)		(4,967	)
Issuance of 10,014 shares of common stock for the exercise of stock options		-		132		-			-			132
Non-cash stock compensation expense		-		171		-			-			171
Dividends declared of $0.12 per share of common stock		-		-		(2,735	)		-			(2,735	)
Net income		-		-		5,787			-			5,787
Balances at March 31, 2025	$	31	$	180,552	$	(14,012	)	$	(136,899	)	$	29,672

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NRC HEALTH

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, unaudited)

	Three months ended
	March 31,
	2026			2025
Cash flows from operating activities:
Net income	$	3,222		$	5,787
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		2,169			1,542
Deferred income tax expense (benefit)		(36	)		1,860
Reserve for uncertain tax positions		(56	)		76
Non-cash share-based compensation expense		1,608			171
Change in fair value of contingent consideration		-			31
Loss on extinguishment of debt		-			67
Amortization of debt issuance costs		27			15
Net changes in assets and liabilities:
Trade accounts receivable		275			(272	)
Prepaid expenses and other current and long-term assets		(1,627	)		(2,419	)
Deferred contract costs, net		(625	)		24
Operating lease assets and liabilities, net		(30	)		(26	)
Accounts payable		942			627
Accrued expenses, wages, and bonuses		(889	)		(472	)
Income taxes receivable and payable		1,265			(80	)
Deferred revenue		935			(285	)
Net cash provided by operating activities		7,180			6,646

Cash flows from investing activities:
Capital expenditures		(1,834	)		(2,986	)
Net cash used in investing activities		(1,834	)		(2,986	)

Cash flows from financing activities:
Borrowings on notes payable		-			27,738
Payments on notes payable		(1,030	)		(28,724	)
Borrowings on revolving loan		2,500			8,000
Payments on revolving loan		(2,500	)		(4,503	)
Payment of debt issuance costs		-			(62	)
Payments on finance lease obligations		(3	)		(2	)
Proceeds from the exercise of share-based awards		139			132
Payment of acquisition contingent consideration		(484	)		(280	)
Repurchase of shares for treasury		(1,935	)		(4,920	)
Payment of dividends on common stock		(3,625	)		(2,770	)
Net cash used in financing activities		(6,938	)		(5,391	)

Change in cash and cash equivalents		(1,592	)		(1,731	)
Cash and cash equivalents at beginning of period		4,139			4,233
Cash and cash equivalents at end of period	$	2,547		$	2,502

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NRC HEALTH

CONSOLIDATED STATEMENTS OF CASH FLOWS, Continued

(In thousands)

	Three months ended
	March 31,
	2026		2025
Supplemental disclosure of cash paid for:
Interest expense, net of capitalized amounts	$	1,247	$	774
Income taxes			$	80
Income taxes (federal)	$	-
Income taxes (state and local)	$	26
Supplemental disclosure of non-cash investing and financing activities:
Purchase of property and equipment in accounts payable and accrued expenses	$	450	$	2,131
Repurchase of shares for treasury in accounts payable and accrued expenses	$	151	$	47
Debt issuance costs included in accrued expenses	$	-	$	81
New debt issued to existing lender	$	-	$	34,396
Debt extinguished using proceeds from new debt	$	-	$	62,076
Noncash borrowings on long-term debt for accrued interest and debt issuance costs	$	-	$	351

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NRC HEALTH

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(1)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Our condensed consolidated balance sheet at December 31, 2025, was derived from our audited consolidated balance sheet as of that date. All other financial statements contained herein are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) that we consider necessary for a fair presentation of financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States.

Information and footnote disclosures included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in our Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2026.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Deferred Contract Costs

We defer incremental costs of obtaining customer contracts. These costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. We deferred incremental costs of obtaining a contract of $908,000 and $354,000 in the three-month periods ended March 31, 2026, and 2025, respectively. Deferred contract costs, net of accumulated amortization was $3.1 million and $2.5 million at March 31, 2026, and December 31, 2025, respectively. Total amortization by expense classification for the three-month periods ended March 31, 2026, and 2025 was as follows (in thousands):

	2026		2025
Direct expenses	$	32	$	20
Selling, general, and administrative expenses	$	240	$	356
Total amortization	$	272	$	376

Fair Value Measurements

Our contingent consideration liability was measured at fair value on a recurring basis using significant unobservable inputs (Level 3). The measurement period for the contingent consideration arrangement was completed as of December 31, 2025. The remaining liability was settled during the quarter and no balance remained at March 31, 2026.

Commitments and Contingencies

There were no material changes to the Company’s commitments, contingencies, or legal proceedings from those disclosed in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025.

Recently Adopted Accounting Standards

We elected the practical expedient under ASU 2025-05 to estimate expected credit losses for current accounts receivable and current contract assets by assuming current conditions as of the balance-sheet date remain unchanged over the remaining life of the assets. The adoption and election did not have a material impact on our condensed consolidated financial statements or related disclosures.

Table of Contents

Recent Accounting Pronouncements Not Yet Adopted

We monitor recently issued accounting pronouncements to assess their potential impact on our consolidated financial statements and related disclosures. The following Accounting Standards Updates (“ASUs”) have been issued but not yet adopted. The Company has evaluated or is currently evaluating each standard to determine the impact of adoption.

In February 2024, the FASB issued ASU 2024-03, which provides improvements to the disclosure requirements for expenses. The update primarily impacts disclosures by requiring entities to provide additional detail about the natural classification of significant expenses that are included in relevant income statement line items. ASU 2024-03 is effective for the Company for annual reporting periods beginning after December 15, 2026, and interim periods thereafter. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial position or results of operations, but it will result in expanded expense disclosures beginning with the Company’s annual financial statements for the year ending December 31, 2027.

In September 2025, the FASB issued ASU 2025-06, which provides targeted improvements to the accounting for internal-use software. The update replaces the current project stage model with a principles-based framework and requires capitalization to begin when management authorizes and commits funding, and project completion is probable. ASU 2025-06 is effective for the Company for annual reporting periods beginning after December 15, 2027, including interim periods within those years. The Company is currently evaluating the effect of adopting this standard, and the impact is not yet known or reasonably estimable. The Company will determine the transition method for adoption and does not plan to adopt before the effective date.

(2)

CONTRACTS WITH CUSTOMERS

We derive a majority of our revenue from renewable subscription‑based service agreements with our customers. These arrangements represent a single promise to stand ready to provide services over the contractual term and are recognized ratably as the related services are provided. As a result, the significant majority of our revenue is recognized over time.

Revenue recognized over time totaled $33.3 million and $31.0 million for the three months ended March 31, 2026 and 2025, respectively. Revenue associated with performance obligations satisfied at a point in time, including one‑time specified services, as well as revenue from fixed, non‑subscription and unit‑priced service arrangements, was not material for either period.

Total revenue for the three months ended March 31, 2026, was $34.8 million, compared to $33.6 million for the three months ended March 31, 2025, with the increase primarily attributable to growth in subscription‑based services.

Our revenue recognition patterns during the quarter are consistent with those disclosed in our Annual Report on Form 10‑K.

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands):

	March 31, 2026		December 31, 2025
Trade accounts receivables	$	10,833	$	11,108
Contract assets included in other current assets	$	75	$	132

Deferred revenue, current portion	$	17,192	$	16,201
Noncurrent deferred revenue included in other long-term liabilities	$	18	$	74

Deferred revenue increased by $1.0 million primarily due to new billings exceeding revenue recognized during the period.

We have elected to apply the practical expedient to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Total remaining contract revenue for contracts with original duration of greater than one year expected to be recognized in the future related to performance obligations that are unsatisfied at March 31, 2026, approximated $194.5 million, of which $61.5 million is expected to be recognized over the next 12 months, with the remainder recognized thereafter.

Table of Contents

(3)

INCOME TAXES

The effective tax rate was 26% and 25% for the three-month periods ended March 31, 2026, and 2025, respectively. The increase in the effective tax rate was primarily driven by a higher impact from non-deductible executive compensation under IRC Section 162(m).

(4)

NOTES PAYABLE

Our long‑term debt consists of amounts outstanding under the Credit Agreement entered into in February 2025, as described in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025. There were no amendments, modifications, or new debt issuances during the three months ended March 31, 2026. Our long-term debt consists of the following (in thousands):

	March 31, 2026			December 31, 2025
Delayed Draw Term Loan	$	78,376		$	79,406
Less: current portion		(4,015	)		(4,014	)
Less: unamortized debt issuance costs		(344	)		(371	)
Notes payable, net of current portion	$	74,017		$	75,021

As of March 31, 2026, we were in compliance with all financial covenants.

(5)

SHARE-BASED COMPENSATION

Our 2025 Omnibus Incentive Plan (the “2025 Omnibus Incentive Plan”), which became effective on May 7, 2025, provides for the granting of equity-based awards, as described in our Annual Report on Form 10-K for the year ended December 31, 2025. At March 31, 2026, 3.9 million shares of common stock were available for issuance pursuant to future grants under the plan.

Service-Based Stock Option Awards

We grant stock options to directors and select executives with vesting based on specified service periods. Vesting terms vary with each grant and option awards are generally five to ten years following the date of grant. We recognize compensation expense on a straight-line basis over the service period specified in the award. We granted 17,638 and 11,021 service-based stock option awards during the three-month period ended March 31, 2026 and 2025, respectively.

The fair value of service-based stock options granted in 2026 was estimated using a Black-Scholes valuation model with the following weighted average assumptions:

	2026
Expected dividend yield at date of grant		3.49	%
Expected stock price volatility		34.51	%
Risk-free interest rate		3.85	%
Expected life of options (in years)		5.0

The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.

Table of Contents

The following table summarizes service-based stock option activity for the three-month period ended March 31, 2026:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Terms (Years)		Aggregate Intrinsic Value (In thousands)
Outstanding at December 31, 2025		608,782	$	27.52
Granted		17,638	$	22.01
Exercised		9,145	$	15.23
Expired		-
Forfeited		-
Outstanding at March 31, 2026		617,275	$	27.54		7.05	$	-
Exercisable at March 31, 2026		401,138	$	33.13		6.17	$	-

Performance-Based Stock Option Awards

We also grant stock options to selected executives with vesting contingent upon meeting certain Company-wide performance goals. The performance goals for options issued in 2024 are based on reaching a total recurring contract value target, measured at the end of the performance period, December 31, 2026. Vesting is also dependent upon remaining in our employment through the performance period. The performance awards issued in 2024 have a six-year contractual term. We recognize compensation expense prospectively from the date it is deemed probable that the performance goal will be met through the end of the performance period. We did not recognize compensation expense related to performance-based awards in 2025 or 2026 since achieving the performance goals was not deemed probable. There was no activity related to performance‑based stock option awards during the three months ended March 31, 2026.

As of March 31, 2026, the total unrecognized compensation cost related to non-vested performance-based and service-based stock option awards was approximately $1.4 million which was expected to be recognized over a weighted average period of 1.6 years.

There was $139,000 and $132,000 of cash received from stock options exercised during the three-month periods ended March 31, 2026 and 2025, respectively. We recognized $245,000 and $171,000 of non-cash compensation expense for the three-month periods ended March 31, 2026, and 2025, respectively, which is included in selling, general, and administrative expenses.

Non-vested Stock Awards and Restricted Stock Units

No shares of non-vested restricted stock awards (RSAs) were granted during the three-month periods ended March 31, 2026 and 2025. At March 31, 2026 and December 31, 2025, there were 829,000 non-vested restricted stock awards outstanding with total remaining unrecognized compensation expense of $7.7 million expected to be recognized over a weighted average period of 2.1 years. We recognized non-cash compensation expense of $1.0 million for the three-month period ended March 31, 2026, related to non-vested stock, which is included in selling, general, and administrative expenses. No expense was recognized for the three-month period ended March 31, 2025.

We granted 160,000 restricted stock units (RSUs) during the three months ended March 31, 2026. No RSUs were granted in 2025. RSUs do not carry dividend or voting rights prior to vesting. At March 31, 2026, 160,000 RSUs were outstanding, with total remaining unrecognized compensation expense of $2.4 million expected to be recognized over a weighted‑average period of 1.8 years. We recognized non‑cash compensation expense of $331,000 for the three months ended March 31, 2026, related to RSUs, which is included in selling, general, and administrative expenses. No expense was recognized for the three-month period ended March 31, 2025.

Table of Contents

(6)

GOODWILL AND OTHER INTANGIBLE ASSETS

The carrying amount of goodwill totaled $66,152 at March 31, 2026, and no impairments were recognized during the three month-period then ended.

Intangible assets consisted of the following (in thousands):

	March 31, 2026			December 31, 2025
Non-amortizing intangible assets:
Indefinite trade name	$	1,191		$	1,191
Amortizing intangible assets:
Customer related		9,772			9,772
Technology		2,790			2,790
Trade names		1,572			1,572
Total amortizing intangible assets		14,134			14,134
Accumulated amortization		(13,160	)		(13,098	)
Other intangible assets, net	$	2,165		$	2,227

(7)

EARNINGS PER SHARE

Basic net income per share was computed using the weighted-average shares of common stock outstanding during the period.

Diluted net income per share was computed using the weighted-average shares of common stock and, if dilutive, the potential common stock outstanding during the period. Potential shares of common stock consist of the incremental common stock issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options and restricted stock units is reflected in diluted earnings per share by application of the treasury stock method.

We had 370,699 and 427,838 options of common stock for the three-month periods ended March 31, 2026, and 2025, respectively, which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive. Performance-based stock option awards have not been included in the computation since the conditions have not been met.

	For the Three Months Ended March 31, 2026			For the Three Months Ended March 31, 2025
	(In thousands, except per share data)
Numerator for net income per share – basic:
Net income	$	3,222		$	5,787
Allocation of distributed and undistributed income to unvested restricted stock shareholders		(133	)		-
Net income attributable to common shareholders		3,089			5,787
Denominator for net income per share – basic:
Weighted average shares of common stock outstanding – basic		21,799			22,972
Net income per share – basic	$	0.14		$	0.25

Numerator for net income per share – diluted:
Net income attributable to common shareholders for basic computation		3,089			5,787
Denominator for net income per share – diluted:
Weighted average shares of common stock outstanding – basic		21,799			22,972
Weighted average effect of dilutive securities – stock options		56			2
Weighted average effect of dilutive securities – restricted stock units		56			0
Denominator for diluted earnings per share – adjusted weighted average shares		21,911			22,974
Net income per share – diluted	$	0.14		$	0.25

Table of Contents

(8)

Segment Information

The Company assesses segment reporting in accordance with ASC 280, Segment Reporting. Based on how the business is managed and the financial information reviewed by our Chief Operating Decision Maker (“CODM”), who is our Chief Executive Officer, the Company operates as one operating segment and one reportable segment.

The CODM evaluates the Company’s performance and allocates resources based on consolidated net income, which is the primary measure used to assess results against forecasts and historical trends. Because the Company has a single operating segment, our segment results are identical to the amounts presented in our Consolidated Statements of Income, and we have no inter‑segment revenues or transfers.

In addition to consolidated net income, the CODM is regularly provided supplemental information regarding certain management bonuses (when applicable), noncash stock compensation expense, and the related income tax, as presented below for the three months ending (in thousands):

	March 31, 2026		March 31, 2025
Noncash stock compensation		1,608		171
Tax benefit on noncash stock compensation		262		43

Table of Contents

(9)

Subsequent Event

On April 27, 2026, the Compensation and Talent Committee of our Board of Directors approved amendments to equity awards granted to certain executives in 2025. The amendments eliminated the Company’s right to repurchase the shares underlying these awards if the executives’ employment terminated under certain circumstances prior to the third anniversary of the respective grant dates. The impacted executives were also awarded bonuses intended to cover their anticipated tax obligations in connection with these amendments.

The amendments and related bonuses are expected to result in approximately $9.4 million of expense during the second quarter of 2026, consisting of (i) approximately $6.5 million of non-cash accelerated equity compensation expense, substantially all of which would otherwise have been recognized ratably through the second quarter of 2028, and (ii) approximately $2.9 million of cash bonus expense, primarily related to tax payments. The Company’s effective tax rate for the second quarter and the remainder of 2026 is expected to be impacted by the non-deductibility of these amounts.

ITEM 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our results of operations and financial condition should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q.

Our purpose is to humanize healthcare and support organizations in their understanding of each unique individual. Our commitment to Human Understanding® helps leading healthcare systems improve their operations through understanding each person they serve not as point-in-time insights, but as an ongoing relationship. Our end-to-end solutions enable our customers to understand what matters most to each person they serve – before, during, after, and beyond clinical encounters – to gain a longitudinal understanding of how life and health intersect, with the goal of developing lasting, trusting relationships. Our ability to measure what matters most and systematically capture, analyze, and deliver insights based on self-reported information from patients, families, and consumers is critical in today’s healthcare market. We believe access to, analysis of, and acting on our extensive individual-driven information is increasingly valuable as healthcare providers need to better understand and engage the people they serve to create long-term relationships, build loyalty, and improve processes.

Our portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. We partner with customers across the continuum of healthcare services and believe this cross-continuum positioning is a unique and an increasingly important capability as the evolving healthcare landscape drives its constituents towards a more collaborative and integrated service model.

Table of Contents

Results of Operations

The following table sets forth, for the periods indicated, selected financial information derived from our condensed consolidated financial statements and the percentage change in such items versus the prior comparable period, as well as other key financial metrics. The discussion that follows the information should be read in conjunction with our condensed consolidated financial statements.

Three Months Ended March 31, 2026, Compared to Three Months Ended March 31, 2025

	(In thousands, except percentages) Three Months Ended March 31,						Percentage Increase (Decrease)
	2026			2025			2026 over 2025
Revenue	$	34,803		$	33,551			4
Direct expenses		13,646			13,057			5
Selling, general, and administrative		13,419			10,356			30
Depreciation and amortization		2,169			1,542			41
Operating income		5,569			8,596			(35	)
Total other expense		(1,190	)		(873	)		36
Provision for income taxes		1,157			1,936			(40	)
Effective Tax Rate		26	%		25	%		1
Operating margin		16	%		26	%		(10	)
Total Recurring Contract Value	$	152,070		$	134,371			13
Cash provided by operating activities		7,180			6,646			8

Revenue. Revenue in the 2026 period increased compared to the 2025 period by $1.3 million. This was mainly from $0.6 million higher recurring revenue from existing customers compared to the prior year, and $0.5 million higher revenue from new customers, compared to the prior year.

Direct expenses. Direct expenses consist primarily of salaries and employee benefits, employee travel and lodging, materials, contract labor, third party software subscription costs, hosted customer conferences, and other direct expenses associated with revenue. Personnel costs within direct expenses are associated with individuals in product delivery, customer support, thought leadership, conference support, technology infrastructure, and product development. Direct expenses represented 39% of revenue for both 2026 and 2025. Direct expenses increased to $13.6 million in 2026 from $13.1 million in 2025, primarily driven by higher third‑party software subscription costs and increased spending on IT contractor services related to continued investments in technology and development.

Selling, general, and administrative expenses. Selling, general, and administrative expenses consist of salaries and employee benefits, commission and amortization of deferred commission, stock-based compensation, employee travel and lodging, third party software subscription and platform costs, marketing costs, facility expenses, office expenses, fees for professional services, provision for credit losses, and other operational expenses. Personnel costs within selling, general, and administrative expenses are associated with individuals in sales, marketing, accounting, business development, human resources, administrative, product development, internal information systems, and executive management. Selling, general, and administrative expenses increased to $13.4 million for the three months ended March 31, 2026, from $10.4 million for the same period in 2025. The increase was primarily driven by $1.4 million of higher stock‑based compensation related to executive leadership and approximately $0.5 million of executive salary expense that was not present in the prior‑year period. The remaining increase was attributable to higher computer software subscription expenses to support ongoing technology investments, regulatory-related accruals, and the timing of corporate‑related expenses.

Depreciation and amortization. Depreciation and amortization expenses increased in the 2026 period compared to the 2025 period due to the completion of our headquarters building renovations in June 2025.

Operating income and margin. Operating income decreased in the 2026 period compared to the 2025 period due to the increased compensation related to our executive leadership transition and increased investment in technology.

Total other expense. Total other expense increased in the 2026 period compared to the 2025 period due to higher interest expense due to a higher balance on the Delayed Draw Term Loan.

Table of Contents

Provision for income taxes and effective tax rate. Provision for income taxes decreased in the 2026 period compared to the 2025 period primarily due to decreased taxable income, partially offset by an increase in the effective tax rate. The effective tax rate increased in the 2026 period due to executive compensation subject to the deductibility limitations under Section 162(m), which did not affect the effective tax rate in the first quarter of 2025.

Total Recurring Contract Value (TRCV). TRCV at March 31, 2026, was higher compared to March 31, 2025, primarily due to sales to new and existing customers and to improved retention of contracts with existing customers. We view TRCV as a leading indicator of our future revenue trends. TRCV represents the total annualized contract value of recurring amounts under customer contracts that are in effect or contractually committed as of the most recent quarter-end and are expected to be in force over the subsequent 12 months, based on contractual pricing and term provisions. TRCV is calculated using contracted recurring fees and assumes no upsells, downsells, price changes, early terminations, or non-renewals, unless we have been notified of such changes by the customer as of the measurement date. TRCV is an operating metric and is not a measure of revenue recognized under U.S. GAAP. The timing and amount of revenue we recognize under ASC 606 may differ from the pattern implied by TRCV due to allocation of transaction price and the timing of satisfaction of performance obligations. As a result, there is typically a lag between changes in TRCV and changes in our reported revenue. Generally, if we are able to sustain growth in TRCV, we would expect revenue growth to follow within subsequent periods, although intervening factors may affect this relationship.

Recent Developments

In April 2026, the Compensation and Talent Committee of our Board of Directors approved amendments to equity awards granted to certain executives in 2025. The amendments eliminated the Company’s right to repurchase the shares underlying these awards if the executives’ employment terminated under certain circumstances prior to the third anniversary of the respective grant dates. The impacted executives were also awarded bonuses intended to cover their anticipated tax obligations in connection with these amendments.

Non-GAAP Financial Measures

In addition to consolidated GAAP financial measures, we review various non-GAAP financial measures that management believes to be important in the evaluation of its operating results and performance, including “Adjusted Net Income,” “Adjusted Earnings per Share,” “Adjusted EBITDA,” “Adjusted EBITDA Margin,” “Free Cash Flow,” and “Free Cash Flow Margin.”

We believe Adjusted Net Income, Adjusted Earnings per Share, Adjusted EBITDA, and Adjusted EBITDA Margin are helpful supplemental measures to assist management and investors in evaluating our operating results as (i) they exclude certain items that are unusual in nature or whose fluctuation from period to period do not necessarily correspond to changes in the operations of our business, and (ii) the exclusion of non-cash stock compensation is useful for investors applying certain valuation metrics and is consistent with the leverage ratio for our credit facility. Adjusted Net Income represents net income adjusted to add back certain management bonuses and non-cash stock compensation and the related tax. Adjusted EBITDA represents net income before interest, taxes, depreciation, amortization, certain management bonuses, and non-cash stock compensation items. Adjusted EBITDA Margin represents Adjusted EBITDA divided by our revenue.

We consider Free Cash Flow to be a measure that provides useful information to management and investors about our liquidity. Free Cash Flow does not represent residual cash flow available for discretionary expenditures. We define Free Cash Flow as net cash provided by operating activities less capital expenditures. Free Cash Flow Margin represents Free Cash Flow divided by our revenue.

We view Adjusted Net Income, Adjusted Earnings per Share, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, and Free Cash Flow Margin as operating performance measures. As such, we believe the most directly comparable GAAP financial measures to Adjusted Net Income and Adjusted Earnings per Share are GAAP Net Income and GAAP Earnings per Share, respectively, the most directly comparable GAAP financial measure to Adjusted EBITDA and Adjusted EBITDA Margin is GAAP Net Income and GAAP Net Income Margin, and the most directly comparable GAAP financial measure to Free Cash Flow and Free Cash Flow Margin is GAAP Net Cash Provided by Operating Activities and GAAP Net Cash Provided by Operating Activities Margin.

Table of Contents

Non-GAAP measures are supplemental financial measures of our performance and should not be considered substitutes for net income, earnings per share, or any other measure derived in accordance with GAAP. This information should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items or events being adjusted. In addition, other companies may use different measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP.

Adjusted Net Income and Adjusted Earnings per Share

The following table presents a reconciliation of GAAP net income and GAAP earnings per share to adjusted net income and adjusted earnings per share, respectively, for each of the periods indicated (in thousands excluding earnings per share):

	Three Months Ended March 31,
	2026			2025

Net income	$	3,222		$	5,787
Add back:
Non-cash stock compensation		1,608			171
Tax on stock compensation		(262	)		(43	)
Adjusted net income	$	4,568		$	5,915

Earnings per share of common stock, diluted	$	0.14		$	0.25
Adjusted earnings per share of common stock, diluted	$	0.21		$	0.26
Weighted average shares and share equivalents outstanding, diluted		21,911			22,974

Adjusted EBITDA and Adjusted EBITDA Margin

The following table presents a reconciliation of GAAP net income and GAAP net income margin to adjusted EBITDA and adjusted EBITDA margin, respectively, for each of the periods indicated (in thousands):

	Three Months Ended March 31,
	2026			2025

Net income	$	3,222		$	5,787
Add back:
Depreciation and amortization		2,169			1,542
Interest expense		1,255			899
Income taxes		1,157			1,936
Non-cash stock compensation		1,608			171
Adjusted EBITDA	$	9,411		$	10,335

Net income margin		9.3	%		17.2	%
Adjusted EBITDA margin		27.0	%		30.8	%

Table of Contents

Free Cash Flow and Free Cash Flow Margin

The following table presents a reconciliation of GAAP net cash provided by operating activities and net cash provided by operating activities margin to free cash flow and free cash flow margin, respectively, for each of the periods indicated (in thousands):

	Three Months Ended March 31,
	2026			2025

Net cash provided by operating activities	$	7,180		$	6,646
Less:
Capital expenditures		1,834			2,986
Free cash flow	$	5,346		$	3,660

Net cash provided by operating activities margin	20.6		%		19.8	%
Free cash flow margin		15.4	%		10.9	%

Liquidity and Capital Resources

Our Board of Directors has established priorities for capital allocation, which include funding of innovation and growth investments, including merger and acquisition activity as well as internal projects, and returning capital to shareholders through dividends and share repurchases.

As of March 31, 2026, our principal sources of liquidity included $2.5 million of cash and cash equivalents, up to $30.0 million of unused borrowings under our Revolving Loan and an additional $27.6 million on our Delayed Draw Term Loan.

Our cash flows from operating activities primarily consist of net income adjusted for non-cash items including depreciation and amortization, deferred income taxes, share-based compensation, and the effect of working capital changes. Cash provided by operating activities increased primarily due to working capital changes, partially offset by a decrease in net income. Working capital changes were mainly driven by trade accounts receivable and prepaid expenses primarily due to timing of billings and payments, and higher deferred revenue. Cash provided by operating activities was also partially offset by an increase in net income net of non-cash items.

See the Condensed Consolidated Statements of Cash Flows included in this report for the detail of our operating cash flows.

We had a working capital deficit of $18.5 million and $16.4 million on March 31, 2026, and December 31, 2025, respectively. The change was primarily due to decreases in cash and cash equivalents and increases in accounts payable, deferred revenue, and income taxes payable. Cash and cash equivalents decreased mainly due to the payment of dividends and the repurchase of shares of our common stock for treasury. The decrease in cash and cash equivalents was partially offset by cash from operating activities. Our working capital is significantly impacted by our large deferred revenue balances which will vary based on the timing and frequency of billings on annual agreements. Notwithstanding our working capital deficit on March 31, 2026, we believe that our existing sources of liquidity, including cash and cash equivalents, borrowing availability, and operating cash flows will be sufficient to meet our projected capital and debt maturity needs for the foreseeable future.

Cash used in investing activities primarily consisted of capitalized internal-use software and purchases of property and equipment including computer software and hardware, building improvements, and furniture and equipment.

Cash used in financing activities consisted of payments of dividends on our common stock, payments on our Delayed Draw Term Loan, repurchases of common stock, and cash to pay contingent consideration related to our 2024 acquisition of Nobl Health.

Table of Contents

Our material cash requirements include the following contractual and other obligations:

Dividends

Cash dividends of $3.6 million were paid in the three months ended March 31, 2026. Additional dividends of $3.6 million were declared in the three months ended March 31, 2026, and paid in April 2026. The dividends were paid from cash on hand and borrowings on our Revolving Loan. Our Board of Directors considers whether to declare a dividend and the amount of any dividends declared on a quarterly basis.

Capital Expenditures

We paid cash of $1.8 million for capital expenditures in the three months ended March 31, 2026. These expenditures consisted primarily of computer hardware and software and costs related to software development for our Human Understanding® solutions.

Debt

Our credit agreement (the “Credit Agreement”), includes (i) a $30.0 million revolving credit facility (the “Revolving Loan”) and (ii) a $110.0 million delayed draw-down term facility (the “Delayed Draw Term Loan” and, together with the Revolving Loan, the “Credit Facilities”). The Delayed Draw Term Loan includes an accordion feature that, so long as no event of default exists or would exist after giving effect to such increase, allows us to request an increase in the Delayed Draw Term Loan of up to the lesser of (x) $25.0 million and (y) our EBITDA as of the preceding four fiscal quarters, exercisable in increments of $10.0 million (or the remaining available amount of the accordion, if less). We may use the Delayed Draw Term Loan to fund permitted future business acquisitions, repurchases of our common stock, capital expenditures, or payment of dividends and the Revolving Loan to fund ongoing working capital needs and for other general corporate purposes.

Interest accrues and is payable monthly at a floating rate equal to the one-month Term SOFR plus a percentage per annum determined by our cash flow leverage ratio, ranging from 2.25% to 2.75% (6.02% at March 31, 2026).

The outstanding balance on the Delayed Draw Term Loan was $78.4 million at March 31, 2026. Principal amounts outstanding are due and payable monthly during the term of the Delayed Draw Term Loan, in equal monthly installments to amortize the aggregate outstanding principal balance by (i) 5% during each of the first three years and (ii) 7.5% during each of the fourth and fifth years following the date of such loan. All outstanding principal and interest on the Delayed Draw Term Loan are due and payable in full at the maturity date, February 6, 2030. We had the availability to borrow an additional $27.6 million on the Delayed Draw Term Loan at March 31, 2026, excluding the accordion feature.

Principal amounts outstanding under the Revolving Loan are due and payable in full at maturity at February 6, 2028. As of March 31, 2026, we had no borrowings outstanding and the availability to borrow $30.0 million on the Revolving Loan. Our weighted average short-term borrowings for the three-month periods ended March 31, 2026, and 2025 were $1.9 million and $2.0 million, respectively. The weighted average interest rate on short-term borrowings during the three-month periods ended March 31, 2026, and 2025 was 6.04% and 6.67%, respectively.

We are obligated to pay ongoing unused commitment fees quarterly in arrears at a percentage per annum determined by our cash flow leverage ratio, ranging from 0.15% to 0.30%, based on the actual daily unused portions of the Revolving Loan and the Delayed Draw Term Loan, respectively.

The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants), and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our common stock, and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x and a cash flow leverage ratio of 3.50x or less for all testing periods throughout the term of the Credit Facilities. As of March 31, 2026, we were in compliance with our financial covenants.

Leases

We have lease arrangements for certain computer, office, printing, and mail inserting equipment as well as office and data center space. As of March 31, 2026, we had fixed lease payments of $493,000 and $8,000 for operating and finance leases, respectively payable within 12 months.

Table of Contents

Taxes

The liability for gross unrecognized tax benefits related to uncertain tax positions was $2.3 million as of March 31, 2026. See Note 3, "Income Taxes", to the Condensed Consolidated Financial Statements contained in this report for income tax related information.

Stock Repurchase Program

In March 2026, our Board of Directors approved a stock repurchase program authorizing the repurchase up to $60.0 million of our outstanding common stock through March 31, 2028 (the “2026 Program”). Under this authorization, may repurchase shares from time to time in the open market, through privately negotiated transactions, and/or other means in compliance with the Securities and Exchange Act of 1934 and the rules and regulations thereunder. Open market repurchases may be structured to occur in accordance with the requirements of Rule 10b-18 under the Exchange Act. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of shares of common stock under this authorization. The timing, manner, price, and amount of any repurchases will be determined by the Company at its discretion, and will depend on a variety of factors, including business, economic and market conditions, prevailing stock prices, corporate and regulatory requirements, and other considerations. The repurchase program may be suspended or discontinued at any time.

During the three months ended March 31, 2026, we repurchased 109,701 shares of our common stock for an aggregate of $1.9 million.

Critical Accounting Estimates

There have been no changes to our critical accounting estimates described in the Annual Report on Form 10-K for the year ended December 31, 2025, that have a material impact on our Condensed Consolidated Financial Statements and the related Notes.

Table of Contents

ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

There are no material changes to the disclosures regarding our market risk exposures made in its Annual Report on Form 10-K for the year ended December 31, 2025.

ITEM 4.

Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report, and our Chief Executive Officer and our Chief Financial Officer, have concluded that, as of the end of such period, our disclosure controls and procedures were effective.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Accordingly, effective internal control over financial reporting can only provide reasonable assurance of achieving its control objectives.

We have confidence in our internal controls and procedures. Nevertheless, our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure procedures and controls or our internal controls will prevent all errors or intentional fraud. An internal control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of such internal controls are met. Further, the design of an internal control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. As a result of the inherent limitations in all internal control systems, no evaluation of controls can provide absolute assurance that all our control issues and instances of fraud, if any, have been detected.

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – Other Information

ITEM 1.

Legal Proceedings

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. For additional information, see Note 1, under the heading “Commitments and Contingencies,” to our condensed consolidated financial statements. Regardless of the final outcome, any legal proceedings, claims, inquiries and investigations, however, can impose a significant burden on management and employees, may include costly defense and settlement costs, and could cause harm to our reputation and brand, and other factors.

ITEM 1A.

Risk Factors

The significant risk factors known to us that could materially adversely affect our business, financial condition, or operating results are described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025.

Table of Contents

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds

Our Credit Agreement provides that, in order for us to pay dividends or repurchase our common stock, there must be no default or event of default existing or that would result from such payment and we must show that we would comply with the Credit Agreement’s fixed charge coverage ratio and consolidated cash flow leverage ratio after giving pro forma effect to such payment.

The table below summarizes repurchases of common stock during the three months ended March 31, 2026.

Period	Total Number of Shares Purchased		Average Price Paid per Share ⁽¹⁾		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs⁽²⁾		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs⁽²⁾

Jan 1 – Jan 31, 2026		-		-		-	$	-
Feb 1 – Feb 28, 2026		-		-		-		-
Mar 1 – Mar 31, 2026		109,701		17.51		109,701		58,066,938
Total		109,701				109,701	$	58,066,938

(1)	The average price paid per share excludes excise tax incurred on stock repurchases. For the quarter ended March 31, 2026, excise tax expense totaled $17,624.
(2)	In March 2026, our Board of Directors authorized the 2026 Program, which authorizes the repurchase up to $60.0 million of our outstanding common stock through March 31, 2028. During the three months ended March 31, 2026, we repurchased 109,701 shares of our common stock for an aggregate of $1.9 million.

ITEM 5.

Other Information

During the first quarter of 2026, no director or officer adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.

Table of Contents

ITEM 6.

Exhibits

The exhibits listed in the exhibit index below are filed as part of this Quarterly Report on Form 10-Q.

EXHIBIT INDEX

Exhibit Number	Exhibit Description

(3.1)	Certificate of Incorporation of the Company, effective June 30, 2021 [Incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed on July 2, 2021 (File No. 001-35929)]

(3.2)	Certificate of Amendment to Certificate of Incorporation of the Company, dated April 15, 2026 [Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 20, 2026 (File No. 001-35929)]

(3.3)	Amended and Restated Bylaws of the Company as of April 15, 2026 [Incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on April 20, 2026 (File No. 001-35929)]

(4.1)	Certificate of Incorporation of the Company, effective June 30, 2021 [Incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed on July 2, 2021 (File No. 001-35929)]

(4.2)	Certificate of Amendment to Certificate of Incorporation of the Company, dated April 15, 2026 [Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 20, 2026 (File No. 001-35929)]

(4.3)	Amended and Restated Bylaws of the Company as of April 15, 2026 [Incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on April 20, 2026 (File No. 001-35929)]

(31.1)**	Certification by the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

(31.2)**	Certification by the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

(32)***	Written Statement of the Chief Executive Officer (Principal Executive Officer) and the Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350

(101) **	Financial statements from the Quarterly Report on Form 10-Q of NRC Health for the quarter ended March 31, 2026, formatted in Inline eXtensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Notes to Condensed Consolidated Financial Statements, and (vi) document and entity information.

(104) **	Cover Page Interactive Data File (formatted in the Inline XBRL and contained in Exhibit 101).

** Filed herewith

*** Furnished herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NRC HEALTH


Date: May 5, 2026	By:	/s/ Trent S. Green
		Trent S. Green
		Chief Executive Officer (Principal Executive Officer)



Date: May 5, 2026	By:	/s/ Shane Harrison
		Shane Harrison Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 ex_952771.htm EXHIBIT 31.1

Exhibit 31.1

Certification of Chief Executive Officer (Principal Executive Officer)

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

I, Trent S. Green, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of NRC Health;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2026

/s/ Trent S. Green

Trent S. Green

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex_952770.htm EXHIBIT 31.2

Exhibit 31.2

Certification of Chief Financial Officer (Principal Financial Officer)

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

I, Shane Harrison, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of NRC Health;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2026

/s/ Shane Harrison

Shane Harrison
Chief Financial Officer

(Principal Financial Officer)

EX-32 4 ex_952769.htm EXHIBIT 32

Exhibit 32

Certification Pursuant to 18 U.S.C. Section 1350
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the accompanying Quarterly Report on Form 10-Q of NRC Health (the “Company”) for the three-month period ended March 31, 2026 (the “Report”), I, Trent S. Green, Chief Executive Officer (Principal Executive Officer) of the Company, and I, Shane Harrison, Chief Financial Officer (Principal Financial Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, based on my knowledge, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Trent S. Green
	Trent S. Green Chief Executive Officer (Principal Executive Officer)


	/s/ Shane Harrison
	Shane Harrison Chief Financial Officer (Principal Financial Officer)

	Date: May 5, 2026

A signed original of this written statement required by Section 906 has been provided to NRC Health and will be retained by NRC Health and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 5 nrc-20260331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Contracts With Customers link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Notes Payable link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Share-Based Compensation link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Goodwill and Other Intangible Assets link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Segment Information link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Subsequent Event link:calculationLink link:definitionLink link:presentationLink 995445 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995446 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995447 - Disclosure - Note 2 - Contracts With Customers (Tables) link:calculationLink link:definitionLink link:presentationLink 995448 - Disclosure - Note 4 - Notes Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 995449 - Disclosure - Note 5 - Share-Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 995450 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 995452 - Disclosure - Note 8 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 995453 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995454 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) link:calculationLink link:definitionLink link:presentationLink 995455 - Disclosure - Note 2 - Contracts With Customers 1 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995456 - Disclosure - Note 2 - Contracts With Customers 2 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995457 - Disclosure - Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) link:calculationLink link:definitionLink link:presentationLink 995458 - Disclosure - Note 3 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995459 - Disclosure - Notes 4 - Notes Payable - Summary of Notes Payable (Details) link:calculationLink link:definitionLink link:presentationLink 995460 - Disclosure - Note 5 - Share-Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995461 - Disclosure - Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995462 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) link:calculationLink link:definitionLink link:presentationLink 995463 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 8 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 8 - Segment Information - Schedule of Segment Information (Details) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 9 - Subsequent Event (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 nrc-20260331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 nrc-20260331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 nrc-20260331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Statistical Measurement [Axis] Note To Financial Statement Details Textual us-gaap_EmployeeBenefitsAndShareBasedCompensation Employee Benefits and Share-Based Compensation Significant Accounting Policies Provision for income taxes Shares of common stock for the exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) Note 1 - Summary of Significant Accounting Policies ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Note 2 - Contracts With Customers ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Note 4 - Notes Payable Trading Arrangements, by Individual [Table] Note 5 - Share-Based Compensation Material Terms of Trading Arrangement [Text Block] Note 6 - Goodwill and Other Intangible Assets Note 7 - Earnings Per Share Note 8 - Segment Information Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Minimum [Member] Notes 4 - Notes Payable - Summary of Notes Payable (Details) us-gaap_TreasuryStockSharesAcquired Purchase of shares of treasury stock (in shares) Selling, General and Administrative Expense [Member] Represents the expense related to selling, general and administrative. Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Statistical Measurement [Domain] Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Maximum [Member] Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Note 7 - Earnings Per Share - Net Income Per Share Computation (Details) Schedule of Long-Term Debt Instruments [Table] Note 8 - Segment Information - Schedule of Segment Information (Details) Notes To Financial Statements us-gaap_IncreaseDecreaseInAccountsReceivable Trade accounts receivable Notes To Financial Statements [Abstract] us-gaap_TreasuryStockValue Treasury stock, 9,329,252 and 7,989,028 Common shares in 2025 and 2024, respectively, at cost Cash flows from operating activities: Cash flows from investing activities: us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Cash flows from financing activities: us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Delayed Draw Term Loan (DDTL) [Member] us-gaap_PaymentsOfDebtIssuanceCosts Payment of debt issuance costs us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_CapitalizedContractCostAmortizationPeriod Capitalized Contract Cost, Amortization Period (Year) Term Loan us-gaap_IncreaseDecreaseInDeferredCharges Deferred contract costs, net us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent us-gaap_SecuredDebtCurrent Less: current portion Granted, weighted average exercise price (in dollars per share) Commitments and Contingencies, Policy [Policy Text Block] Exercised, weighted average exercise price (in dollars per share) us-gaap_DividendsCommonStockCash Dividends declared Accounting Policies [Abstract] Allowance for doubtful accounts Common Stock, Dividends, Per Share, Declared Common Stock, Dividends, Per Share, Declared (in dollars per share) Debt issuance costs included in accrued expenses nrc_AllocatedShareBasedCompensationExpenseBenefit Share-Based Payment Arrangement, Expense Amount of expense (benefit) for award under share-based payment arrangements. Income Statement [Abstract] us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Net income (loss) attributable to common shareholders for basic computation us-gaap_NumberOfOperatingSegments Number of Operating Segments us-gaap_NumberOfReportableSegments Number of Reportable Segments us-gaap_DeferredIncomeTaxExpenseBenefit Deferred income taxes Segment Reporting [Text Block] Treasury Stock, Shares (in shares) Treasury Stock, Common [Member] The 2025 Omnibus Incentive Plan [Member] Relating to the 2025 Omnibus Incentive Plan. Award Type [Axis] Segment Reporting [Table Text Block] us-gaap_PreferredStockValue Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued Adjustments to reconcile net income to net cash provided by operating activities: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net income (loss) attributable to common shareholders us-gaap_Liabilities Total liabilities Plan Name [Axis] Plan Name [Domain] Amortization of debt issuance costs us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and shareholders’ equity us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense us-gaap_DeferredRevenuePeriodIncreaseDecrease Deferred Revenue, Period Increase (Decrease) Segment Reporting [Table] us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current and noncurrent assets New debt issued to existing lender Represents the cash flow impact of debt issued to an existing lender. Selling, general, and administrative Non-cash share-based compensation expense Noncash stock compensation Subsequent Event [Member] us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Noncash stock compensation us-gaap_CostsAndExpenses Total operating expenses us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic Allocation of distributed and undistributed income to unvested restricted stock shareholders Income Tax Disclosure [Text Block] nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet Operating lease assets and liabilities, net Amount of increase (decrease) in operating lease assets after deduction of operating lease liabilities. Share-Based Payment Arrangement [Text Block] Change in assets and liabilities: us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Preferred stock, shares issued (in shares) Accounting Standards Update and Change in Accounting Principle [Table] Preferred stock, shares authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Amortization of Capitalized Contract Cost [Table Text Block] Tabular disclosure of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer. Preferred stock, par value (in dollars per share) us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Change in cash and cash equivalents us-gaap_DeferredFinanceCostsNet Less: unamortized debt issuance costs us-gaap_TreasuryStockValueAcquiredCostMethod Purchase of shares treasury stock New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Statement [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Prepaid expenses Other income (expense): us-gaap_RepaymentsOfLinesOfCredit Payments on revolving loan Statement of Financial Position [Abstract] us-gaap_NonoperatingIncomeExpense Total other expense us-gaap_FinanceLeasePrincipalPayments Payments on finance lease obligations us-gaap_IncomeTaxesPaidNet Income taxes Income taxes receivable us-gaap_RepaymentsOfNotesPayable Borrowings on notes payable Long-Term Debt, Type [Axis] Product and Service [Domain] Product and Service [Axis] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Other noncurrent assets us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization Net property and equipment us-gaap_PaymentsForRepurchaseOfCommonStock Repurchase of shares for treasury dei_DocumentType Document Type Operating expenses: Document Information [Line Items] Document Quarterly Report us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, number of options (in shares) Document Information [Table] us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Expired, number (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Exercisable, number (in shares) dei_EntityInteractiveDataCurrent Entity Interactive Data Current us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Exercisable, weighted average exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Beginning balance, outstanding, number of options (in shares) Outstanding, number (in shares) Document Transition Report Diluted (in shares) Denominator for diluted earnings per share – adjusted weighted average shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Beginning balance, outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Statement [Line Items] Outstanding, aggregate intrinsic value Common stock, shares issued (in shares) Earnings per share of common stock: Common stock, shares outstanding (in shares) Award Type [Domain] Intangible Asset, Indefinite-Lived, Class [Domain] Risk-free interest rate Common stock, shares authorized (in shares) Expected stock price volatility us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Weighted average effect of dilutive securities (in shares) Basic (in shares) Weighted average common shares outstanding – basic (in shares) Expected dividend yield at date of grant Basic (in dollars per share) Net income (loss) per share – basic (in dollars per share) Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Current portion of notes payable, net of unamortized debt issuance costs Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,966,504 in 2025 and 31,072,144 in 2024, outstanding 22,637,252 in 2025 and 23,083,116 in 2024 Intangible Asset, Indefinite-Lived, Class [Axis] Intangible Asset and Goodwill [Table Text Block] Notes payable, net of current portion and unamortized debt issuance costs Effective Income Tax Rate Reconciliation [Table] Income taxes (state and local) Income taxes (state and local) nrc_CashBonusExpense Cash Bonus Expense Amount of expense related to cash bonuses. Direct Expenses [Member] Related to direct expenses. us-gaap_IncomeTaxPaidFederalAfterRefundReceived Income taxes (Federal) Accounts payable Intangible assets, net us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_TableTextBlock Notes Tables Borrowings on revolving loan Document Fiscal Period Focus us-gaap_FiniteLivedIntangibleAssetsGross Amortizing intangible assets Document Fiscal Year Focus Depreciation and amortization nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod Incremental Costs of Obtaining a Contract, Deferred During Period Represents the amount of incremental costs of obtaining a contract deferred during the period. Amendment Flag Technology-Based Intangible Assets [Member] Common Stock [Member] Change in fair value of contingent consideration us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Indefinite trade name us-gaap_Goodwill Goodwill Subsequent Events [Text Block] Accrued expenses Document Period End Date Dividends payable Granted, number of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Legal Entity [Axis] Accrued wages and bonuses Significant Accounting Policies [Text Block] EX-101.PRE 9 nrc-20260331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2026	Apr. 30, 2026
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2026
Document Transition Report	false
Entity File Number	001-35929
Entity Registrant Name	NRC Health
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-0634000
Entity Address, Address Line One	1245 Q Street
Entity Address, City or Town	Lincoln
Entity Address, State or Province	NE
Entity Address, Postal Zip Code	68508
City Area Code	402
Local Phone Number	475-2525
Title of 12(b) Security	Common Stock, $.001 par value
Trading Symbol	NRC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		22,536,696
Entity Central Index Key	0000070487
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 2,547	$ 4,139
Trade accounts receivable, less allowance for credit losses of $90 and $80, respectively	10,833	11,108
Prepaid expenses	5,662	3,914
Income taxes receivable	481	528
Other current assets	461	520
Total current assets	19,984	20,209
Net property and equipment	40,305	40,474
Intangible assets, net	2,165	2,227
Goodwill	66,152	66,152
Deferred contract costs, net	3,123	2,498
Other noncurrent assets	2,830	3,318
Total assets	134,559	134,878
Current liabilities:
Current portion of notes payable, net of unamortized debt issuance costs	4,015	4,014
Accounts payable	2,227	1,169
Accrued wages and bonuses	6,603	7,218
Accrued expenses	2,582	2,897
Dividends payable	3,606	3,625
Deferred revenue	17,192	16,201
Income Taxes Payable	1,768	550
Other current liabilities	477	946
Total current liabilities	38,470	36,620
Notes payable, net of current portion and unamortized debt issuance costs	74,017	75,021
Deferred income taxes	5,999	5,984
Other long-term liabilities	2,578	3,263
Total liabilities	121,064	120,888
Shareholders’ equity:
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued	0	0
Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,966,504 in 2025 and 31,072,144 in 2024, outstanding 22,637,252 in 2025 and 23,083,116 in 2024	32	32
Additional paid-in capital	185,627	183,880
Accumulated deficit	(17,682)	(17,298)
Treasury stock, 9,329,252 and 7,989,028 Common shares in 2025 and 2024, respectively, at cost	(154,482)	(152,624)
Total shareholders’ equity	13,495	13,990
Total liabilities and shareholders’ equity	$ 134,559	$ 134,878

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Allowance for doubtful accounts	$ 90	$ 80
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	110,000,000	110,000,000
Common stock, shares issued (in shares)	31,975,649	31,966,504
Common stock, shares outstanding (in shares)	22,536,696	22,637,252
Treasury Stock, Shares (in shares)	9,438,953	9,329,252

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References + Details

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References + Details

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Revenue	$ 34,803	$ 33,551
Operating expenses:
Direct	13,646	13,057
Selling, general, and administrative	13,419	10,356
Depreciation and amortization	2,169	1,542
Total operating expenses	29,234	24,955
Operating income	5,569	8,596
Other income (expense):
Interest income	35	19
Interest expense	(1,255)	(899)
Other, net	30	7
Total other expense	(1,190)	(873)
Income before income taxes	4,379	7,723
Provision for income taxes	1,157	1,936
Net income	$ 3,222	$ 5,787
Earnings per share of common stock:
Basic (in dollars per share)	$ 0.14	$ 0.25
Diluted (in dollars per share)	$ 0.14	$ 0.25
Weighted average shares and share equivalents outstanding:
Basic (in shares)	21,799	22,972
Diluted (in shares)	21,911	22,974

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Balances at Dec. 31, 2024	$ 31	$ 180,249	$ (17,064)	$ (131,932)	$ 31,284
Purchase of shares treasury stock	0	0	0	(4,967)	(4,967)
Issuance of shares of common stock for the exercise of stock options	0	132	0	0	132
Non-cash stock compensation expense	0	171	0	0	171
Dividends declared	0	0	(2,735)	0	(2,735)
Net income	0	0	5,787	0	5,787
Net income	0	0	5,787	0	5,787
Balances at Mar. 31, 2025	31	180,552	(14,012)	(136,899)	29,672
Balances at Dec. 31, 2025	32	183,880	(17,298)	(152,624)	13,990
Purchase of shares treasury stock	0	0	0	(1,858)	(1,858)
Issuance of shares of common stock for the exercise of stock options	0	139	0	0	139
Non-cash stock compensation expense	0	1,608	0	0	1,608
Dividends declared	0	0	(3,606)	0	(3,606)
Net income	0	0	3,222	0	3,222
Net income	0	0	3,222	0	3,222
Balances at Mar. 31, 2026	$ 32	$ 185,627	$ (17,682)	$ (154,482)	$ 13,495

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19

Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 44: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

- Definition

Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Purchase of shares of treasury stock (in shares)	109,701	307,709
Shares of common stock for the exercise of stock options (in shares)	9,145	10,014
Common Stock, Dividends, Per Share, Declared	$ 0.16	$ 0.12
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)	9,145	10,014
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.16	$ 0.12

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

- Definition

Number of shares that have been repurchased during the period and are being held in treasury.

+ References

+ Details

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Cash flows from operating activities:
Net income	$ 3,222,000	$ 5,787,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,169,000	1,542,000
Deferred income taxes	(36,000)	1,860,000
Reserve for uncertain tax positions	(56,000)	76,000
Non-cash share-based compensation expense	1,608,000	171,000
Change in fair value of contingent consideration	0	31,000
Loss on extinguishment of debt	0	67,000
Amortization of debt issuance costs	27,000	15,000
Change in assets and liabilities:
Trade accounts receivable	275,000	(272,000)
Prepaid expenses and other current and noncurrent assets	(1,627,000)	(2,419,000)
Deferred contract costs, net	(625,000)	24,000
Operating lease assets and liabilities, net	(30,000)	(26,000)
Accounts payable	942,000	627,000
Accrued expenses, wages and bonuses	(889,000)	(472,000)
Income taxes receivable and payable	1,265,000	(80,000)
Deferred revenue	935,000	(285,000)
Net cash provided by operating activities	7,180,000	6,646,000
Cash flows from investing activities:
Capital expenditures	1,834,000	2,986,000
Net cash used in investing activities	(1,834,000)	(2,986,000)
Cash flows from financing activities:
Payments on notes payable	0	27,738,000
Borrowings on notes payable	(1,030,000)	(28,724,000)
Borrowings on revolving loan	2,500,000	8,000,000
Payments on revolving loan	(2,500,000)	(4,503,000)
Payment of debt issuance costs	0	(62,000)
Payments on finance lease obligations	(3,000)	(2,000)
Proceeds from the exercise of share-based awards	139,000	132,000
Payment of acquisition contingent consideration	(484,000)	(280,000)
Repurchase of shares for treasury	(1,935,000)	(4,920,000)
Payment of dividends on common stock	(3,625,000)	(2,770,000)
Net cash used in financing activities	(6,938,000)	(5,391,000)
Change in cash and cash equivalents	(1,592,000)	(1,731,000)
Cash and cash equivalents at beginning of period	4,139,000	4,233,000
Cash and cash equivalents at end of period	2,547,000	2,502,000
Supplemental disclosure of cash paid for:
Interest expense, net of capitalized amounts	1,247,000	774,000
Income taxes		80,000
Income taxes (Federal)	0
Income taxes (state and local)	26,000
Purchase of property and equipment in accounts payable and accrued expenses	450,000	2,131,000
Repurchase of shares for treasury in accounts payable and accrued expenses	151,000	47,000
Debt issuance costs included in accrued expenses	0	81,000
New debt issued to existing lender	0	34,396,000
Debt extinguished using proceeds from new debt	0	62,076,000
Noncash borrowings on long-term debt for accrued interest and debt issuance costs	0	351,000
Income taxes (state and local)	26,000
Purchase of property and equipment in accounts payable and accrued expenses	450,000	2,131,000
Repurchase of shares for treasury in accounts payable and accrued expenses	151,000	47,000
Debt issuance costs included in accrued expenses	0	81,000
New debt issued to existing lender	0	34,396,000
Debt extinguished using proceeds from new debt	0	62,076,000
Noncash borrowings on long-term debt for accrued interest and debt issuance costs	$ 0	$ 351,000

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Significant Accounting Policies [Text Block]

(1)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Use of Estimates

Deferred Contract Costs

	2026		2025
Direct expenses	$	32	$	20
Selling, general, and administrative expenses	$	240	$	356
Total amortization	$	272	$	376

Fair Value Measurements

Recently Adopted Accounting Standards

Recent Accounting Pronouncements Not Yet Adopted

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Contracts With Customers

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

(2)

CONTRACTS WITH CUSTOMERS

Our revenue recognition patterns during the quarter are consistent with those disclosed in our Annual Report on Form 10‑K.

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands):

	March 31, 2026		December 31, 2025
Trade accounts receivables	$	10,833	$	11,108
Contract assets included in other current assets	$	75	$	132

Deferred revenue, current portion	$	17,192	$	16,201
Noncurrent deferred revenue included in other long-term liabilities	$	18	$	74

Deferred revenue increased by $1.0 million primarily due to new billings exceeding revenue recognized during the period.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Income Taxes

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Income Tax Disclosure [Text Block]

(3)

INCOME TAXES

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Notes Payable

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Debt Disclosure [Text Block]

(4)

NOTES PAYABLE

	March 31, 2026			December 31, 2025
Delayed Draw Term Loan	$	78,376		$	79,406
Less: current portion		(4,015	)		(4,014	)
Less: unamortized debt issuance costs		(344	)		(371	)
Notes payable, net of current portion	$	74,017		$	75,021

As of March 31, 2026, we were in compliance with all financial covenants.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Share-Based Compensation

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

(5)

SHARE-BASED COMPENSATION

Service-Based Stock Option Awards

The fair value of service-based stock options granted in 2026 was estimated using a Black-Scholes valuation model with the following weighted average assumptions:

	2026
Expected dividend yield at date of grant		3.49	%
Expected stock price volatility		34.51	%
Risk-free interest rate		3.85	%
Expected life of options (in years)		5.0

The following table summarizes service-based stock option activity for the three-month period ended March 31, 2026:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Terms (Years)		Aggregate Intrinsic Value (In thousands)
Outstanding at December 31, 2025		608,782	$	27.52
Granted		17,638	$	22.01
Exercised		9,145	$	15.23
Expired		-
Forfeited		-
Outstanding at March 31, 2026		617,275	$	27.54		7.05	$	-
Exercisable at March 31, 2026		401,138	$	33.13		6.17	$	-

Performance-Based Stock Option Awards

Non-vested Stock Awards and Restricted Stock Units

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Intangible Asset and Goodwill [Text Block]

(6)

GOODWILL AND OTHER INTANGIBLE ASSETS

The carrying amount of goodwill totaled $66,152 at March 31, 2026, and no impairments were recognized during the three month-period then ended.

Intangible assets consisted of the following (in thousands):

	March 31, 2026			December 31, 2025
Non-amortizing intangible assets:
Indefinite trade name	$	1,191		$	1,191
Amortizing intangible assets:
Customer related		9,772			9,772
Technology		2,790			2,790
Trade names		1,572			1,572
Total amortizing intangible assets		14,134			14,134
Accumulated amortization		(13,160	)		(13,098	)
Other intangible assets, net	$	2,165		$	2,227

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Earnings Per Share

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Earnings Per Share [Text Block]

(7)

EARNINGS PER SHARE

Basic net income per share was computed using the weighted-average shares of common stock outstanding during the period.

	For the Three Months Ended March 31, 2026			For the Three Months Ended March 31, 2025
	(In thousands, except per share data)
Numerator for net income per share – basic:
Net income	$	3,222		$	5,787
Allocation of distributed and undistributed income to unvested restricted stock shareholders		(133	)		-
Net income attributable to common shareholders		3,089			5,787
Denominator for net income per share – basic:
Weighted average shares of common stock outstanding – basic		21,799			22,972
Net income per share – basic	$	0.14		$	0.25

Numerator for net income per share – diluted:
Net income attributable to common shareholders for basic computation		3,089			5,787
Denominator for net income per share – diluted:
Weighted average shares of common stock outstanding – basic		21,799			22,972
Weighted average effect of dilutive securities – stock options		56			2
Weighted average effect of dilutive securities – restricted stock units		56			0
Denominator for diluted earnings per share – adjusted weighted average shares		21,911			22,974
Net income per share – diluted	$	0.14		$	0.25

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Segment Information

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Segment Reporting [Text Block]

(8)

Segment Information

	March 31, 2026		March 31, 2025
Noncash stock compensation		1,608		171
Tax benefit on noncash stock compensation		262		43

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Subsequent Event

3 Months Ended

Mar. 31, 2026

Notes to Financial Statements

Subsequent Events [Text Block]

(9)

Subsequent Event

XML 27 R17.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements

3 Months Ended

Mar. 31, 2026

Trading Arrangements, by Individual [Table]

Material Terms of Trading Arrangement [Text Block]

ITEM 5.

Other Information

During the first quarter of 2026, no director or officer adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.

Non-Rule 10b5-1 Arrangement Terminated [Flag]

false

Rule 10b5-1 Arrangement Terminated [Flag]

false

Non-Rule 10b5-1 Arrangement Adopted [Flag]

false

Rule 10b5-1 Arrangement Adopted [Flag]

false

XML 28 R18.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2026

Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Deferred Charges, Policy [Policy Text Block]

Deferred Contract Costs

	2026		2025
Direct expenses	$	32	$	20
Selling, general, and administrative expenses	$	240	$	356
Total amortization	$	272	$	376

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

Commitments and Contingencies, Policy [Policy Text Block]

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Standards

Recent Accounting Pronouncements Not Yet Adopted

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

+ Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 1 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Amortization of Capitalized Contract Cost [Table Text Block]

	2026		2025
Direct expenses	$	32	$	20
Selling, general, and administrative expenses	$	240	$	356
Total amortization	$	272	$	376

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 2 - Contracts With Customers (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

	March 31, 2026		December 31, 2025
Trade accounts receivables	$	10,833	$	11,108
Contract assets included in other current assets	$	75	$	132

Deferred revenue, current portion	$	17,192	$	16,201
Noncurrent deferred revenue included in other long-term liabilities	$	18	$	74

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 4 - Notes Payable (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Schedule of Debt [Table Text Block]

	March 31, 2026			December 31, 2025
Delayed Draw Term Loan	$	78,376		$	79,406
Less: current portion		(4,015	)		(4,014	)
Less: unamortized debt issuance costs		(344	)		(371	)
Notes payable, net of current portion	$	74,017		$	75,021

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 5 - Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	2026
Expected dividend yield at date of grant		3.49	%
Expected stock price volatility		34.51	%
Risk-free interest rate		3.85	%
Expected life of options (in years)		5.0

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Terms (Years)		Aggregate Intrinsic Value (In thousands)
Outstanding at December 31, 2025		608,782	$	27.52
Granted		17,638	$	22.01
Exercised		9,145	$	15.23
Expired		-
Forfeited		-
Outstanding at March 31, 2026		617,275	$	27.54		7.05	$	-
Exercisable at March 31, 2026		401,138	$	33.13		6.17	$	-

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 6 - Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Intangible Asset and Goodwill [Table Text Block]

	March 31, 2026			December 31, 2025
Non-amortizing intangible assets:
Indefinite trade name	$	1,191		$	1,191
Amortizing intangible assets:
Customer related		9,772			9,772
Technology		2,790			2,790
Trade names		1,572			1,572
Total amortizing intangible assets		14,134			14,134
Accumulated amortization		(13,160	)		(13,098	)
Other intangible assets, net	$	2,165		$	2,227

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 7 - Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	For the Three Months Ended March 31, 2026			For the Three Months Ended March 31, 2025
	(In thousands, except per share data)
Numerator for net income per share – basic:
Net income	$	3,222		$	5,787
Allocation of distributed and undistributed income to unvested restricted stock shareholders		(133	)		-
Net income attributable to common shareholders		3,089			5,787
Denominator for net income per share – basic:
Weighted average shares of common stock outstanding – basic		21,799			22,972
Net income per share – basic	$	0.14		$	0.25

Numerator for net income per share – diluted:
Net income attributable to common shareholders for basic computation		3,089			5,787
Denominator for net income per share – diluted:
Weighted average shares of common stock outstanding – basic		21,799			22,972
Weighted average effect of dilutive securities – stock options		56			2
Weighted average effect of dilutive securities – restricted stock units		56			0
Denominator for diluted earnings per share – adjusted weighted average shares		21,911			22,974
Net income per share – diluted	$	0.14		$	0.25

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 8 - Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Segment Reporting [Table Text Block]

	March 31, 2026		March 31, 2025
Noncash stock compensation		1,608		171
Tax benefit on noncash stock compensation		262		43

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Incremental Costs of Obtaining a Contract, Deferred During Period	$ 908,000	$ 354,000
Capitalized Contract Cost, Net, Noncurrent	$ 3,123,000		$ 2,498,000
Minimum [Member]
Capitalized Contract Cost, Amortization Period (Year)	3 years
Maximum [Member]
Capitalized Contract Cost, Amortization Period (Year)	5 years

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Capitalized contract cost	$ 272	$ 376
Direct Expenses [Member]
Capitalized contract cost	32	20
Selling, General and Administrative Expense [Member]
Capitalized contract cost	$ 240	$ 356

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 2 - Contracts With Customers 1 (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Revenue from Contract with Customer, Excluding Assessed Tax	$ 34,803	$ 33,551
Deferred Revenue, Period Increase (Decrease)	1,000
Long-Term Contract with Customer [Member]
Revenue, Remaining Performance Obligation, Amount	194,500
Subscription Services [Member] \| Transferred over Time [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 33,300	$ 31,000

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

+ Details

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 2 - Contracts With Customers 2 (Details Textual) - Long-Term Contract with Customer [Member] $ in Millions	Mar. 31, 2026 USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 194.5
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-04-01
Revenue, Remaining Performance Obligation, Amount	$ 61.5
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Trade accounts receivables	$ 10,833	$ 11,108
Contract assets included in other current assets	75	132
Deferred revenue, current portion	17,192	16,201
Noncurrent deferred revenue included in other long-term liabilities	$ 18	$ 74

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 3 - Income Taxes (Details Textual)	3 Months Ended
Note 3 - Income Taxes (Details Textual)	Mar. 31, 2026	Mar. 31, 2025
Effective Income Tax Rate Reconciliation, Percent	26.00%	25.00%

XML 42 R32.htm IDEA: XBRL DOCUMENT

Notes 4 - Notes Payable - Summary of Notes Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Less: current portion	$ (4,015)	$ (4,014)
Less: unamortized debt issuance costs	(344)	(371)
Notes payable, net of current portion	74,017	75,021
Delayed Draw Term Loan (DDTL) [Member]
Term Loan	$ 78,376	$ 79,406

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 5 - Share-Based Compensation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Proceeds from Stock Options Exercised	$ 139,000	$ 132,000
Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares)			829,000
Service based Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	17,638	11,021
Service based Stock Options [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	5 years
Performance based Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	6 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	0
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 1,400,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 7 months 6 days
Share-Based Payment Arrangement, Expense	$ 245,000	$ 171,000
Nonvested [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares)	829,000
Share-Based Payment Arrangement, Expense	$ 1,000,000	$ 0
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 2,400,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 9 months 18 days
Share-Based Payment Arrangement, Expense	$ 331,000	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted	160,000	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number	160,000
The 2025 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant	3,900,000
The 2006 Equity Incentive Plan [Member] \| Nonvested [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 7,700,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 1 month 6 days

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) - Service based Stock Options [Member]	3 Months Ended
	Mar. 31, 2026
Expected dividend yield at date of grant	3.49%
Expected stock price volatility	34.51%
Risk-free interest rate	3.85%
Expected life of options (in years) (Year)	5 years

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)	9,145	10,014
Service based Stock Options [Member]
Beginning balance, outstanding, number of options (in shares)	608,782
Beginning balance, outstanding, weighted average exercise price (in dollars per share)	$ 27.52
Granted, number of options (in shares)	17,638	11,021
Granted, weighted average exercise price (in dollars per share)	$ 22.01
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)	9,145
Exercised, weighted average exercise price (in dollars per share)	$ 15.23
Expired, number (in shares)	0
Forfeited, number of options (in shares)	0
Outstanding, number (in shares)	617,275
Outstanding, weighted average exercise price (in dollars per share)	$ 27.54
Outstanding, weighted average contractual term (Year)	7 years 18 days
Outstanding, aggregate intrinsic value	$ 0
Exercisable, number (in shares)	401,138
Exercisable, weighted average exercise price (in dollars per share)	$ 33.13
Exercisable, weighted average remaining contractual term (Year)	6 years 2 months 1 day
Exercisable, aggregate intrinsic value	$ 0

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 6 - Goodwill and Other Intangible Assets (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Goodwill	$ 66,152	$ 66,152

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

+ Details

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Amortizing intangible assets	$ 14,134	$ 14,134
Accumulated amortization	(13,160)	(13,098)
Other intangible assets, net	2,165	2,227
Customer Relationships [Member]
Amortizing intangible assets	9,772	9,772
Technology-Based Intangible Assets [Member]
Amortizing intangible assets	2,790	2,790
Trade Names [Member]
Amortizing intangible assets	1,572	1,572
Trade Names 1 [Member]
Indefinite trade name	$ 1,191	$ 1,191

XML 48 R38.htm IDEA: XBRL DOCUMENT

Note 7 - Earnings Per Share (Details Textual) - shares	3 Months Ended
Note 7 - Earnings Per Share (Details Textual) - shares	Mar. 31, 2026	Mar. 31, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	370,699	427,838

XML 49 R39.htm IDEA: XBRL DOCUMENT

Note 7 - Earnings Per Share - Net Income Per Share Computation (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Net income	$ 3,222	$ 5,787
Allocation of distributed and undistributed income to unvested restricted stock shareholders	(133)	0
Net income (loss) attributable to common shareholders	$ 3,089	$ 5,787
Weighted average common shares outstanding – basic (in shares)	21,799	22,972
Net income (loss) per share – basic (in dollars per share)	$ 0.14	$ 0.25
Net income (loss) attributable to common shareholders for basic computation	$ 3,089	$ 5,787
Denominator for diluted earnings per share – adjusted weighted average shares (in shares)	21,911	22,974
Net income (loss) per share – diluted (in dollars per share)	$ 0.14	$ 0.25
Share-Based Payment Arrangement, Option [Member]
Weighted average effect of dilutive securities (in shares)	56	2
Restricted Stock Units (RSUs) [Member]
Weighted average effect of dilutive securities (in shares)	56	0

XML 50 R40.htm IDEA: XBRL DOCUMENT

Note 8 - Segment Information (Details Textual)	3 Months Ended
Note 8 - Segment Information (Details Textual)	Mar. 31, 2026
Number of Reportable Segments	1
Number of Operating Segments	1

XML 51 R41.htm IDEA: XBRL DOCUMENT

Note 8 - Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Noncash stock compensation	$ 1,608	$ 171
Noncash stock compensation	$ 262	$ 43

XML 52 R42.htm IDEA: XBRL DOCUMENT

Note 9 - Subsequent Event (Details Textual) - Subsequent Event [Member] $ in Millions	Apr. 27, 2026 USD ($)
Share-Based Payment Arrangement, Expense	$ 9.4
Employee Benefits and Share-Based Compensation	6.5
Cash Bonus Expense	$ 2.9

XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 70 215 1 false 25 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://nrchealth.com/20260331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) Sheet http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Summary of Significant Accounting Policies Sheet http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies Note 1 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Contracts With Customers Sheet http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers Note 2 - Contracts With Customers Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Income Taxes Sheet http://nrchealth.com/20260331/role/statement-note-3-income-taxes Note 3 - Income Taxes Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Notes Payable Notes http://nrchealth.com/20260331/role/statement-note-4-notes-payable Note 4 - Notes Payable Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Share-Based Compensation Sheet http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation Note 5 - Share-Based Compensation Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Goodwill and Other Intangible Assets Sheet http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets Note 6 - Goodwill and Other Intangible Assets Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Earnings Per Share Sheet http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share Note 7 - Earnings Per Share Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Segment Information Sheet http://nrchealth.com/20260331/role/statement-note-8-segment-information Note 8 - Segment Information Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Subsequent Event Sheet http://nrchealth.com/20260331/role/statement-note-9-subsequent-event Note 9 - Subsequent Event Notes 16 false false R17.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 17 false false R18.htm 995445 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies 18 false false R19.htm 995446 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) Sheet http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-tables Note 1 - Summary of Significant Accounting Policies (Tables) Tables http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies 19 false false R20.htm 995447 - Disclosure - Note 2 - Contracts With Customers (Tables) Sheet http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables Note 2 - Contracts With Customers (Tables) Tables http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers 20 false false R21.htm 995448 - Disclosure - Note 4 - Notes Payable (Tables) Notes http://nrchealth.com/20260331/role/statement-note-4-notes-payable-tables Note 4 - Notes Payable (Tables) Tables http://nrchealth.com/20260331/role/statement-note-4-notes-payable 21 false false R22.htm 995449 - Disclosure - Note 5 - Share-Based Compensation (Tables) Sheet http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables Note 5 - Share-Based Compensation (Tables) Tables http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation 22 false false R23.htm 995450 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables) Sheet http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-tables Note 6 - Goodwill and Other Intangible Assets (Tables) Tables http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets 23 false false R24.htm 995451 - Disclosure - Note 7 - Earnings Per Share (Tables) Sheet http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-tables Note 7 - Earnings Per Share (Tables) Tables http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share 24 false false R25.htm 995452 - Disclosure - Note 8 - Segment Information (Tables) Sheet http://nrchealth.com/20260331/role/statement-note-8-segment-information-tables Note 8 - Segment Information (Tables) Tables http://nrchealth.com/20260331/role/statement-note-8-segment-information 25 false false R26.htm 995453 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) Sheet http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual Note 1 - Summary of Significant Accounting Policies (Details Textual) Details http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-tables 26 false false R27.htm 995454 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Sheet http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Details 27 false false R28.htm 995455 - Disclosure - Note 2 - Contracts With Customers 1 (Details Textual) Sheet http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual Note 2 - Contracts With Customers 1 (Details Textual) Details http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables 28 false false R29.htm 995456 - Disclosure - Note 2 - Contracts With Customers 2 (Details Textual) Sheet http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual Note 2 - Contracts With Customers 2 (Details Textual) Details http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables 29 false false R30.htm 995457 - Disclosure - Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Sheet http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Details 30 false false R31.htm 995458 - Disclosure - Note 3 - Income Taxes (Details Textual) Sheet http://nrchealth.com/20260331/role/statement-note-3-income-taxes-details-textual Note 3 - Income Taxes (Details Textual) Details http://nrchealth.com/20260331/role/statement-note-3-income-taxes 31 false false R32.htm 995459 - Disclosure - Notes 4 - Notes Payable - Summary of Notes Payable (Details) Notes http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details Notes 4 - Notes Payable - Summary of Notes Payable (Details) Details 32 false false R33.htm 995460 - Disclosure - Note 5 - Share-Based Compensation (Details Textual) Sheet http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual Note 5 - Share-Based Compensation (Details Textual) Details http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables 33 false false R34.htm 995461 - Disclosure - Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Sheet http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Details 34 false false R35.htm 995462 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Sheet http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Details 35 false false R36.htm 995463 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Details Textual) Sheet http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-details-textual Note 6 - Goodwill and Other Intangible Assets (Details Textual) Details http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-tables 36 false false R37.htm 995464 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Sheet http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Details 37 false false R38.htm 995465 - Disclosure - Note 7 - Earnings Per Share (Details Textual) Sheet http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-details-textual Note 7 - Earnings Per Share (Details Textual) Details http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-tables 38 false false R39.htm 995466 - Disclosure - Note 7 - Earnings Per Share - Net Income Per Share Computation (Details) Sheet http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details Note 7 - Earnings Per Share - Net Income Per Share Computation (Details) Details 39 false false R40.htm 995467 - Disclosure - Note 8 - Segment Information (Details Textual) Sheet http://nrchealth.com/20260331/role/statement-note-8-segment-information-details-textual Note 8 - Segment Information (Details Textual) Details http://nrchealth.com/20260331/role/statement-note-8-segment-information-tables 40 false false R41.htm 995468 - Disclosure - Note 8 - Segment Information - Schedule of Segment Information (Details) Sheet http://nrchealth.com/20260331/role/statement-note-8-segment-information-schedule-of-segment-information-details Note 8 - Segment Information - Schedule of Segment Information (Details) Details 41 false false R42.htm 995469 - Disclosure - Note 9 - Subsequent Event (Details Textual) Sheet http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual Note 9 - Subsequent Event (Details Textual) Details http://nrchealth.com/20260331/role/statement-note-9-subsequent-event 42 false false All Reports Book All Reports nrc-20260331.xsd nrc-20260331_cal.xml nrc-20260331_def.xml nrc-20260331_lab.xml nrc-20260331_pre.xml nrc20260331_10q.htm http://fasb.org/us-gaap/2026 http://xbrl.sec.gov/dei/2026 http://xbrl.sec.gov/ecd/2026 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nrc20260331_10q.htm": { "nsprefix": "nrc", "nsuri": "http://nrchealth.com/20260331", "dts": { "schema": { "local": [ "nrc-20260331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd", "https://xbrl.sec.gov/country/2026/country-2026.xsd", "https://xbrl.sec.gov/currency/2026/currency-2026.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd", "https://xbrl.sec.gov/exch/2026/exch-2026.xsd", "https://xbrl.sec.gov/naics/2026/naics-2026.xsd", "https://xbrl.sec.gov/sic/2026/sic-2026.xsd", "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd" ] }, "calculationLink": { "local": [ "nrc-20260331_cal.xml" ] }, "definitionLink": { "local": [ "nrc-20260331_def.xml" ] }, "labelLink": { "local": [ "nrc-20260331_lab.xml" ] }, "presentationLink": { "local": [ "nrc-20260331_pre.xml" ] }, "inline": { "local": [ "nrc20260331_10q.htm" ] } }, "keyStandard": 202, "keyCustom": 13, "axisStandard": 13, "axisCustom": 0, "memberStandard": 16, "memberCustom": 9, "hidden": { "total": 25, "http://xbrl.sec.gov/ecd/2026": 4, "http://fasb.org/us-gaap/2026": 16, "http://xbrl.sec.gov/dei/2026": 5 }, "contextCount": 70, "entityCount": 1, "segmentCount": 25, "elementCount": 321, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2026": 406, "http://xbrl.sec.gov/dei/2026": 29, "http://xbrl.sec.gov/ecd/2026": 5 }, "report": { "R1": { "role": "http://nrchealth.com/20260331/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DirectOperatingCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "unique": true } }, "R5": { "role": "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "longName": "005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "unique": true } }, "R8": { "role": "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "longName": "007 - Disclosure - Note 1 - Summary of Significant Accounting Policies", "shortName": "Note 1 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "longName": "008 - Disclosure - Note 2 - Contracts With Customers", "shortName": "Note 2 - Contracts With Customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://nrchealth.com/20260331/role/statement-note-3-income-taxes", "longName": "009 - Disclosure - Note 3 - Income Taxes", "shortName": "Note 3 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://nrchealth.com/20260331/role/statement-note-4-notes-payable", "longName": "010 - Disclosure - Note 4 - Notes Payable", "shortName": "Note 4 - Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "longName": "011 - Disclosure - Note 5 - Share-Based Compensation", "shortName": "Note 5 - Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets", "longName": "012 - Disclosure - Note 6 - Goodwill and Other Intangible Assets", "shortName": "Note 6 - Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "longName": "013 - Disclosure - Note 7 - Earnings Per Share", "shortName": "Note 7 - Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://nrchealth.com/20260331/role/statement-note-8-segment-information", "longName": "014 - Disclosure - Note 8 - Segment Information", "shortName": "Note 8 - Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event", "longName": "015 - Disclosure - Note 9 - Subsequent Event", "shortName": "Note 9 - Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies", "longName": "995445 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "longName": "995446 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 1 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables", "longName": "995447 - Disclosure - Note 2 - Contracts With Customers (Tables)", "shortName": "Note 2 - Contracts With Customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://nrchealth.com/20260331/role/statement-note-4-notes-payable-tables", "longName": "995448 - Disclosure - Note 4 - Notes Payable (Tables)", "shortName": "Note 4 - Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables", "longName": "995449 - Disclosure - Note 5 - Share-Based Compensation (Tables)", "shortName": "Note 5 - Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "longName": "995450 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables)", "shortName": "Note 6 - Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-tables", "longName": "995451 - Disclosure - Note 7 - Earnings Per Share (Tables)", "shortName": "Note 7 - Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://nrchealth.com/20260331/role/statement-note-8-segment-information-tables", "longName": "995452 - Disclosure - Note 8 - Segment Information (Tables)", "shortName": "Note 8 - Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "longName": "995453 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 1 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "nrc:IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "nrc:IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "longName": "995454 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)", "shortName": "Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:CapitalizedContractCostAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:CapitalizedContractCostAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual", "longName": "995455 - Disclosure - Note 2 - Contracts With Customers 1 (Details Textual)", "shortName": "Note 2 - Contracts With Customers 1 (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DeferredRevenuePeriodIncreaseDecrease", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "unique": true } }, "R29": { "role": "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual", "longName": "995456 - Disclosure - Note 2 - Contracts With Customers 2 (Details Textual)", "shortName": "Note 2 - Contracts With Customers 2 (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i_2026-03-31_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-date.domain-2026-04-01", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "unique": true } }, "R30": { "role": "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "longName": "995457 - Disclosure - Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)", "shortName": "Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31", "name": "nrc:ContractAssetsIncludedInOtherCurrentAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "unique": true } }, "R31": { "role": "http://nrchealth.com/20260331/role/statement-note-3-income-taxes-details-textual", "longName": "995458 - Disclosure - Note 3 - Income Taxes (Details Textual)", "shortName": "Note 3 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details", "longName": "995459 - Disclosure - Notes 4 - Notes Payable - Summary of Notes Payable (Details)", "shortName": "Notes 4 - Notes Payable - Summary of Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:SecuredDebtCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:SecuredDebtCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "longName": "995460 - Disclosure - Note 5 - Share-Based Compensation (Details Textual)", "shortName": "Note 5 - Share-Based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ProceedsFromStockOptionsExercised", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "nrc:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "nrc:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "unique": true } }, "R34": { "role": "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "longName": "995461 - Disclosure - Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details)", "shortName": "Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31_AwardTypeAxis-ServiceBasedStockOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31_AwardTypeAxis-ServiceBasedStockOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "longName": "995462 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)", "shortName": "Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_AwardTypeAxis-ServiceBasedStockOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "unique": true } }, "R36": { "role": "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-details-textual", "longName": "995463 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Details Textual)", "shortName": "Note 6 - Goodwill and Other Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "longName": "995464 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "shortName": "Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-details-textual", "longName": "995465 - Disclosure - Note 7 - Earnings Per Share (Details Textual)", "shortName": "Note 7 - Earnings Per Share (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details", "longName": "995466 - Disclosure - Note 7 - Earnings Per Share - Net Income Per Share Computation (Details)", "shortName": "Note 7 - Earnings Per Share - Net Income Per Share Computation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "unique": true } }, "R40": { "role": "http://nrchealth.com/20260331/role/statement-note-8-segment-information-details-textual", "longName": "995467 - Disclosure - Note 8 - Segment Information (Details Textual)", "shortName": "Note 8 - Segment Information (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": null, "uniqueAnchor": null }, "R41": { "role": "http://nrchealth.com/20260331/role/statement-note-8-segment-information-schedule-of-segment-information-details", "longName": "995468 - Disclosure - Note 8 - Segment Information - Schedule of Segment Information (Details)", "shortName": "Note 8 - Segment Information - Schedule of Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "unique": true } }, "R42": { "role": "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual", "longName": "995469 - Disclosure - Note 9 - Subsequent Event (Details Textual)", "shortName": "Note 9 - Subsequent Event (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2026-04-27_2026-04-27_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-04-27_2026-04-27_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nrc20260331_10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r736", "r771", "r774" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "lang": { "en-us": { "role": { "label": "Trade accounts receivable, less allowance for credit losses of $90 and $80, respectively", "terseLabel": "Trade accounts receivables", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r861" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Income Taxes Payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r775" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r775" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r782", "r895" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r543", "r585", "r841", "r842", "r843", "r844", "r929", "r991" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "terseLabel": "Non-cash stock compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r367" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r398", "r407", "r408" ] }, "nrc_AllocatedShareBasedCompensationExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "AllocatedShareBasedCompensationExpenseBenefit", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "nrc_AllocatedShareBasedCompensationExpenseBenefit", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense (benefit) for award under share-based payment arrangements." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r93", "r207", "r217" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentFlag", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "nrc_AmortizationOfCapitalizedContractCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "AmortizationOfCapitalizedContractCostTableTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Amortization of Capitalized Contract Cost [Table Text Block]", "documentation": "Tabular disclosure of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Amortization of debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r20", "r298", "r832", "r936" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r162" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Assets", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r55", "r56", "r70", "r119", "r121", "r122", "r167", "r177", "r195", "r199", "r208", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r329", "r451", "r455", "r490", "r526", "r527", "r530", "r539", "r540", "r545", "r609", "r668", "r669", "r680", "r736", "r741", "r742", "r753", "r887", "r888", "r938" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r55", "r56", "r96", "r119", "r121", "r122", "r208", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r329", "r451", "r455", "r490", "r736", "r768", "r887", "r888", "r938" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsCurrentAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AwardTypeAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Change in fair value of contingent consideration", "documentation": "Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement." } } }, "auth_ref": [ "r444", "r831" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CapitalExpendituresIncurredButNotYetPaid", "terseLabel": "Purchase of property and equipment in accounts payable and accrued expenses", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r833" ] }, "us-gaap_CapitalizedContractCostAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CapitalizedContractCostAmortization", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CapitalizedContractCostAmortization", "terseLabel": "Capitalized contract cost", "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r104", "r105", "r221" ] }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CapitalizedContractCostAmortizationPeriod", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CapitalizedContractCostAmortizationPeriod", "terseLabel": "Capitalized Contract Cost, Amortization Period (Year)", "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r764" ] }, "us-gaap_CapitalizedContractCostAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CapitalizedContractCostAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "lang": { "en-us": { "role": { "label": "Capitalized Contract Cost [Axis]", "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer." } } }, "auth_ref": [ "r220" ] }, "us-gaap_CapitalizedContractCostDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CapitalizedContractCostDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "lang": { "en-us": { "role": { "label": "Capitalized Contract Cost [Domain]", "documentation": "Cost capitalized in obtaining and fulfilling contract with customer." } } }, "auth_ref": [ "r220" ] }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CapitalizedContractCostNetNoncurrent", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Deferred contract costs, net", "terseLabel": "Capitalized Contract Cost, Net, Noncurrent", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent." } } }, "auth_ref": [ "r220" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r66", "r113", "r116", "r652", "r940" ] }, "nrc_CashBonusExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "CashBonusExpense", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual" ], "lang": { "en-us": { "role": { "label": "nrc_CashBonusExpense", "terseLabel": "Cash Bonus Expense", "documentation": "Amount of expense related to cash bonuses." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r26", "r113", "r116" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r26" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CityAreaCode", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r645" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common Stock, Dividends, Per Share, Declared (in dollars per share)", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r328", "r330" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r89", "r325", "r526", "r527", "r535", "r744", "r745", "r746", "r748", "r749", "r750", "r751", "r841", "r842", "r844", "r929", "r989", "r991" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r780", "r894", "r941", "r942", "r945" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r89", "r325", "r526", "r527", "r535", "r597" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesIssued", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r89", "r325", "r526", "r527", "r535" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r89", "r325", "r526", "r527", "r535", "r597", "r615", "r892", "r991", "r992" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,966,504 in 2025 and 31,072,144 in 2024, outstanding 22,637,252 in 2025 and 23,083,116 in 2024", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r89", "r308", "r314", "r325", "r526", "r527", "r535", "r548", "r736" ] }, "nrc_ContractAssetsIncludedInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "ContractAssetsIncludedInOtherCurrentAssets", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "lang": { "en-us": { "role": { "label": "nrc_ContractAssetsIncludedInOtherCurrentAssets", "terseLabel": "Contract assets included in other current assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current, that is included in other current assets." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r901" ] }, "us-gaap_ContractWithCustomerDurationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerDurationAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Duration [Axis]", "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts." } } }, "auth_ref": [ "r681", "r687" ] }, "us-gaap_ContractWithCustomerDurationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerDurationDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Duration [Domain]", "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts." } } }, "auth_ref": [ "r681", "r687" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "terseLabel": "Deferred revenue, current portion", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r337", "r338", "r340", "r352", "r655" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "lang": { "en-us": { "role": { "label": "Noncurrent deferred revenue included in other long-term liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r337", "r338", "r340", "r352" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total operating expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r22" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CustomerRelationshipsMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r707", "r867", "r868", "r869", "r870", "r872", "r873", "r876", "r877" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-4-notes-payable" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r30", "r64", "r65", "r72", "r73", "r76", "r78", "r79", "r81", "r82", "r119", "r120", "r256", "r257", "r258", "r259", "r260", "r265", "r266", "r276", "r282", "r283", "r284", "r285", "r286", "r287", "r292", "r299", "r300", "r302", "r457", "r498", "r526", "r527", "r532" ] }, "nrc_DebtExtinguishmentWithNewDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "DebtExtinguishmentWithNewDebt", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Debt extinguished using proceeds from new debt", "documentation": "Amount of debt extinguished with new debt." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-4-notes-payable", "http://nrchealth.com/20260331/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r15", "r38", "r39", "r40", "r65", "r76", "r77", "r78", "r79", "r80", "r82", "r277", "r278", "r279", "r280", "r281", "r283", "r288", "r289", "r290", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r301", "r319", "r457", "r526", "r527", "r532", "r542", "r675", "r676", "r677", "r678", "r679", "r735", "r834", "r835", "r836", "r840", "r935", "r937" ] }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Debt issuance costs included in accrued expenses", "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction." } } }, "auth_ref": [ "r833" ] }, "nrc_DebtIssuedToExistingLender": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "DebtIssuedToExistingLender", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "New debt issued to existing lender", "documentation": "Represents the cash flow impact of debt issued to an existing lender." } } }, "auth_ref": [] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r63", "r69" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsNet", "negatedLabel": "Less: unamortized debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r890", "r934", "r935", "r937" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r4", "r45", "r834", "r839" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Deferred income taxes", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r85", "r411", "r412", "r526", "r527", "r531", "r546" ] }, "us-gaap_DeferredRevenuePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredRevenuePeriodIncreaseDecrease", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredRevenuePeriodIncreaseDecrease", "terseLabel": "Deferred Revenue, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in deferred revenue." } } }, "auth_ref": [] }, "us-gaap_DelayedDrawTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DelayedDrawTermLoanMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-4-notes-payable", "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details" ], "lang": { "en-us": { "role": { "label": "Delayed Draw Term Loan (DDTL) [Member]", "documentation": "Term loan allowing borrower to withdraw predefined amount of preapproved loan within predetermined period." } } }, "auth_ref": [ "r987", "r988" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 0.0 }, "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r4", "r874", "r879" ] }, "nrc_DirectExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "DirectExpensesMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "lang": { "en-us": { "role": { "label": "Direct Expenses [Member]", "documentation": "Related to direct expenses." } } }, "auth_ref": [] }, "us-gaap_DirectOperatingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DirectOperatingCosts", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Direct", "documentation": "The aggregate direct operating costs incurred during the reporting period." } } }, "auth_ref": [ "r17" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r350", "r351", "r683", "r684", "r685", "r686", "r687", "r688", "r689" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r365", "r370", "r399", "r400", "r402", "r691" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-3-income-taxes", "http://nrchealth.com/20260331/role/statement-note-4-notes-payable", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "http://nrchealth.com/20260331/role/statement-note-8-segment-information", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsCommonStockCash", "negatedTerseLabel": "Dividends declared", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r896", "r897" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Dividends payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r775" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentInformationLineItems", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r757" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentTransitionReport", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r758" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentType", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Earnings per share of common stock:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareBasic", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Basic (in dollars per share)", "terseLabel": "Net income (loss) per share \u2013 basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r53", "r102", "r130", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r146", "r149", "r159", "r160", "r161", "r166", "r253", "r306", "r358", "r405", "r439", "r449", "r486", "r487", "r538", "r554", "r661" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareDiluted", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Diluted (in dollars per share)", "terseLabel": "Net income (loss) per share \u2013 diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r53", "r102", "r130", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r149", "r159", "r160", "r161", "r166", "r253", "r306", "r358", "r405", "r439", "r449", "r486", "r487", "r538", "r554", "r661" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r145", "r162", "r163", "r164", "r165", "r333" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-3-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r414", "r693" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-3-income-taxes", "http://nrchealth.com/20260331/role/statement-note-3-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r414", "r415", "r693" ] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeBenefitsAndShareBasedCompensation", "terseLabel": "Employee Benefits and Share-Based Compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [ "r785" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accrued wages and bonuses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r775" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r401" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r401" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-8-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "terseLabel": "Noncash stock compensation", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r398" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeStockOptionMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r755" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityCurrentReportingStatus", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-document-and-entity-information", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables", "http://nrchealth.com/20260331/role/statement-note-3-income-taxes", "http://nrchealth.com/20260331/role/statement-note-3-income-taxes-details-textual", "http://nrchealth.com/20260331/role/statement-note-4-notes-payable", "http://nrchealth.com/20260331/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-details-textual", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-details-textual", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-tables", "http://nrchealth.com/20260331/role/statement-note-8-segment-information", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-details-textual", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-schedule-of-segment-information-details", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-tables", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual", "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r755" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFileNumber", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFilerCategory", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r755" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r762" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r755" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityShellCompany", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r755" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntitySmallBusiness", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r755" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r755" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityComponentDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r52", "r53", "r60", "r88", "r89", "r99", "r100", "r101", "r125", "r126", "r127", "r131", "r139", "r141", "r143", "r168", "r209", "r212", "r252", "r253", "r255", "r305", "r318", "r323", "r324", "r325", "r328", "r330", "r332", "r356", "r357", "r361", "r362", "r405", "r423", "r424", "r435", "r436", "r437", "r440", "r448", "r449", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r473", "r474", "r475", "r476", "r485", "r491", "r492", "r493", "r494", "r495", "r496", "r499", "r507", "r520", "r526", "r527", "r534", "r535", "r543", "r553", "r567", "r568", "r569", "r585", "r633", "r900" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [ "r931", "r932" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeasePrincipalPayments", "negatedLabel": "Payments on finance lease obligations", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r500", "r501" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedTerseLabel": "Accumulated amortization", "documentation": "Amount of accumulated amortization of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r68", "r222", "r241", "r650", "r878" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived, Class [Axis]", "documentation": "Information by class of finite-lived intangible asset." } } }, "auth_ref": [ "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r524", "r525", "r579", "r648", "r650", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r878", "r993", "r994", "r995" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsGross", "terseLabel": "Amortizing intangible assets", "documentation": "Amount, before accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r222", "r241", "r525", "r650", "r878" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived, Class [Domain]", "documentation": "Class of finite-lived intangible asset." } } }, "auth_ref": [ "r235", "r236", "r237", "r238", "r240", "r241", "r243", "r244", "r579", "r648", "r650", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r878", "r993", "r994", "r995" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "negatedLabel": "Loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r4", "r12", "r13" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_Goodwill", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r62", "r67", "r223", "r526", "r527", "r528", "r669", "r674", "r694", "r695", "r696", "r726", "r730", "r736", "r864", "r865", "r928" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Intangible Asset and Goodwill [Text Block]", "documentation": "The entire disclosure for intangible asset and goodwill. Includes, but is not limited to, finite- and indefinite-lived intangible assets, capitalized cost for internal-use software and software to be sold, leased, or marketed." } } }, "auth_ref": [ "r863", "r866" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r16", "r36", "r539", "r541", "r551", "r651", "r657", "r659", "r660", "r664", "r668", "r846", "r849", "r855", "r858", "r859" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-3-income-taxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r119", "r123", "r410", "r414", "r416", "r417", "r418", "r419", "r420", "r428", "r430", "r431", "r432", "r544", "r578", "r583", "r693" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r41", "r46", "r119", "r142", "r143", "r167", "r185", "r199", "r413", "r414", "r429", "r555", "r651", "r657", "r659", "r660", "r693" ] }, "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxPaidFederalAfterRefundReceived", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxPaidFederalAfterRefundReceived", "terseLabel": "Income taxes (Federal)", "documentation": "Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income." } } }, "auth_ref": [ "r115", "r421" ] }, "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Income taxes (state and local)", "terseLabel": "Income taxes (state and local)", "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income." } } }, "auth_ref": [ "r115", "r421" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxesPaidNet", "terseLabel": "Income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r37", "r115", "r421", "r422" ] }, "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Income taxes receivable", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": [ "r770", "r781" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedTerseLabel": "Trade accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "nrc_IncreaseDecreaseInAccruedExpensesWagesBonusesAndProfitSharing": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "IncreaseDecreaseInAccruedExpensesWagesBonusesAndProfitSharing", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Accrued expenses, wages and bonuses", "documentation": "The net change during the reporting period in the aggregate amount of expenses and accrued compensation incurred but not yet paid." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r522", "r831" ] }, "us-gaap_IncreaseDecreaseInDeferredCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInDeferredCharges", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInDeferredCharges", "negatedTerseLabel": "Deferred contract costs, net", "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInIncomeTaxes", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInIncomeTaxes", "terseLabel": "Income taxes receivable and payable", "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets." } } }, "auth_ref": [ "r831" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Change in assets and liabilities:" } } }, "auth_ref": [] }, "nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet", "negatedLabel": "Operating lease assets and liabilities, net", "documentation": "Amount of increase (decrease) in operating lease assets after deduction of operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other current and noncurrent assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "terseLabel": "Weighted average effect of dilutive securities (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r150", "r151", "r152", "r161", "r369" ] }, "nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "terseLabel": "Incremental Costs of Obtaining a Contract, Deferred During Period", "documentation": "Represents the amount of incremental costs of obtaining a contract deferred during the period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Indefinite-Lived, Class [Axis]", "documentation": "Information by class of indefinite-lived intangible asset." } } }, "auth_ref": [ "r235", "r239", "r242", "r650", "r699", "r700", "r701", "r710", "r711", "r725" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill", "terseLabel": "Indefinite trade name", "documentation": "Amount of indefinite-lived intangible asset. Excludes goodwill." } } }, "auth_ref": [ "r222", "r242", "r650" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Indefinite-Lived, Class [Domain]", "documentation": "Class of indefinite-lived intangible asset." } } }, "auth_ref": [ "r235", "r239", "r242", "r650", "r699", "r700", "r701", "r710", "r711", "r725" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r759" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Amount, after accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill." } } }, "auth_ref": [ "r235", "r526", "r527", "r529", "r873", "r875" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseNonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r181", "r657", "r660", "r787" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Interest expense, net of capitalized amounts", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r109", "r111", "r114" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r167", "r180", "r199", "r668", "r786" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LegalEntityAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-document-and-entity-information", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables", "http://nrchealth.com/20260331/role/statement-note-3-income-taxes", "http://nrchealth.com/20260331/role/statement-note-3-income-taxes-details-textual", "http://nrchealth.com/20260331/role/statement-note-4-notes-payable", "http://nrchealth.com/20260331/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-details-textual", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-details-textual", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-tables", "http://nrchealth.com/20260331/role/statement-note-8-segment-information", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-details-textual", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-schedule-of-segment-information-details", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-tables", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual", "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r55", "r56", "r119", "r121", "r122", "r208", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r329", "r452", "r455", "r456", "r490", "r596", "r663", "r680", "r753", "r783", "r887", "r938", "r939" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r92", "r526", "r527", "r537", "r550", "r736", "r741", "r742", "r834", "r838", "r862", "r933" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r55", "r56", "r59", "r75", "r119", "r121", "r122", "r208", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r329", "r452", "r455", "r456", "r490", "r736", "r887", "r938", "r939" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LocalPhoneNumber", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermContractWithCustomerMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual" ], "lang": { "en-us": { "role": { "label": "Long-Term Contract with Customer [Member]", "documentation": "Contract with customer in which duration is classified as long-term." } } }, "auth_ref": [ "r681", "r687" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtNoncurrent", "terseLabel": "Notes payable, net of current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r772", "r777" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Notes payable, net of current portion and unamortized debt issuance costs", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r772", "r776", "r777" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-4-notes-payable", "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r65", "r76", "r77", "r78", "r79", "r80", "r526", "r527", "r532", "r881", "r882", "r883" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-4-notes-payable", "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r11", "r65", "r76", "r77", "r78", "r79", "r80", "r526", "r527", "r532", "r881", "r882", "r883" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MaximumMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r57", "r58", "r172", "r261", "r262", "r263", "r264", "r364", "r394", "r395", "r396", "r409", "r488", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r521", "r563", "r564", "r577", "r588", "r589", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r646", "r647", "r673", "r690", "r694", "r697", "r698", "r731", "r732", "r733", "r734", "r738", "r889", "r891" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MinimumMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r57", "r58", "r172", "r261", "r262", "r263", "r264", "r364", "r394", "r395", "r396", "r409", "r488", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r521", "r563", "r564", "r577", "r588", "r589", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r646", "r647", "r673", "r690", "r694", "r697", "r698", "r731", "r732", "r733", "r738", "r889", "r891" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r760" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r110" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r110" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "totalLabel": "Net income (loss) attributable to common shareholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r53", "r103", "r135", "r136", "r137", "r138", "r146", "r147", "r158", "r161", "r309", "r311", "r315", "r449" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "terseLabel": "Net income (loss) attributable to common shareholders for basic computation", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r103", "r148", "r154", "r155", "r156", "r157", "r158", "r161" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r48", "r49", "r50", "r51", "r52", "r53", "r106", "r107", "r108", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r137", "r144", "r166", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r303", "r304", "r305", "r306", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r403", "r404", "r405", "r406", "r423", "r424", "r425", "r426", "r427", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r489", "r502", "r503", "r504", "r505", "r506", "r507", "r520", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r580" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [ "r144" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r760" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r760" ] }, "nrc_NoncashBorrowingsOnLongtermDebtForAccruedInterestAndDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "NoncashBorrowingsOnLongtermDebtForAccruedInterestAndDebtIssuanceCosts", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Noncash borrowings on long-term debt for accrued interest and debt issuance costs", "documentation": "Amount of noncash borrowings on long-term debt for accrued interest and debt issuance costs." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other expense", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r19", "r766", "r767", "r862" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "nrc_NonvestedMember": { "xbrltype": "domainItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "NonvestedMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonvested [Member]", "documentation": "Information pertaining to nonvested shares." } } }, "auth_ref": [] }, "nrc_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Current portion of notes payable, net of unamortized debt issuance costs", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r775" ] }, "nrc_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfOperatingSegments", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-8-segment-information-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r669", "r848" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfReportableSegments", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-8-segment-information-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r665", "r672", "r848" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingExpensesAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r657", "r660", "r664", "r766", "r767", "r846", "r849", "r855", "r858", "r859", "r862" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r95", "r736" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Other noncurrent assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r63", "r69" ] }, "us-gaap_OtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherIntangibleAssetsNet", "terseLabel": "Other intangible assets, net", "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other." } } }, "auth_ref": [ "r773" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r64", "r71", "r74", "r736" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r84", "r778" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Other, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r21", "r729" ] }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "negatedTerseLabel": "Allocation of distributed and undistributed income to unvested restricted stock shareholders", "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": [ "r158", "r763" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities", "negatedLabel": "Payment of acquisition contingent consideration", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r2" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Repurchase of shares for treasury", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r24" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedTerseLabel": "Payment of debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Payment of dividends on common stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r24" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "terseLabel": "Capital expenditures", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r23" ] }, "nrc_PerformanceBasedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "PerformanceBasedStockOptionsMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Performance based Stock Options [Member]", "documentation": "Represents the Performance based Stock Options" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927" ] }, "nrc_PolicyTable": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "PolicyTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "nrc_PolicyTable" } } }, "auth_ref": [] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r317", "r769", "r779", "r893", "r941", "r942", "r944" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r60", "r88", "r324", "r526", "r527", "r534", "r597" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesIssued", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r60", "r88", "r317", "r324", "r526", "r527", "r534" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockValue", "terseLabel": "Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r60", "r88", "r308", "r313", "r324", "r526", "r527", "r534", "r547", "r736" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r94", "r218", "r219", "r654" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Borrowings on revolving loan", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r9", "r834", "r836" ] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromNotesPayable", "terseLabel": "Payments on notes payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from the exercise of share-based awards", "terseLabel": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r8" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductOrServiceAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r202", "r523", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r649", "r656", "r659", "r660", "r681", "r683", "r737", "r738", "r739", "r740", "r743", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r827", "r828", "r829", "r830", "r885", "r886", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductsAndServicesDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r202", "r523", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r649", "r656", "r659", "r660", "r681", "r683", "r737", "r738", "r739", "r740", "r743", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r827", "r828", "r829", "r830", "r885", "r886", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 0.0 }, "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 }, "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Net income", "totalLabel": "Net income", "terseLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r53", "r55", "r56", "r97", "r98", "r112", "r119", "r121", "r122", "r124", "r130", "r139", "r142", "r143", "r208", "r253", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r306", "r329", "r358", "r405", "r439", "r449", "r450", "r453", "r454", "r487", "r490", "r539", "r541", "r552", "r584", "r616", "r631", "r632", "r651", "r727", "r728", "r752", "r784", "r887" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "terseLabel": "Net property and equipment", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r765", "r880" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r57", "r58", "r172", "r261", "r262", "r263", "r264", "r363", "r364", "r394", "r395", "r396", "r402", "r409", "r488", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r563", "r564", "r577", "r588", "r589", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r646", "r647", "r673", "r690", "r694", "r697", "r698", "r731", "r732", "r733", "r734", "r738", "r746", "r884", "r889", "r891", "r930" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r57", "r58", "r172", "r261", "r262", "r263", "r264", "r363", "r364", "r394", "r395", "r396", "r402", "r409", "r488", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r563", "r564", "r577", "r588", "r589", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r646", "r647", "r673", "r690", "r694", "r697", "r698", "r731", "r732", "r733", "r734", "r738", "r746", "r884", "r889", "r891", "r930" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLinesOfCredit", "negatedLabel": "Payments on revolving loan", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r25", "r834", "r836" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfNotesPayable", "negatedTerseLabel": "Borrowings on notes payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r25" ] }, "nrc_ReserveForUncertainTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "ReserveForUncertainTaxPositions", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Reserve for uncertain tax positions", "label": "nrc_ReserveForUncertainTaxPositions", "documentation": "The current period expense charged against earnings to reserve for uncertain tax positions." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r90", "r91", "r326", "r526", "r527", "r536", "r549", "r571", "r576", "r582", "r598", "r736" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r52", "r53", "r125", "r126", "r127", "r131", "r139", "r141", "r143", "r209", "r212", "r252", "r253", "r255", "r305", "r323", "r332", "r356", "r357", "r361", "r362", "r405", "r423", "r424", "r435", "r436", "r437", "r440", "r448", "r449", "r460", "r461", "r462", "r463", "r465", "r466", "r469", "r485", "r499", "r520", "r543", "r567", "r569", "r585", "r896", "r897", "r991" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r167", "r178", "r179", "r193", "r199", "r202", "r204", "r205", "r349", "r350", "r351", "r523", "r657", "r660" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r47", "r339", "r341", "r342", "r343", "r344", "r345", "r347", "r348", "r351", "r353" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RevenueRemainingPerformanceObligation", "terseLabel": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r44" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r346" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r346" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r760" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r760" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-4-notes-payable-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r845" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-details-textual", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-tables" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r149", "r153", "r159", "r161" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-details-textual", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-tables" ], "lang": { "en-us": { "role": { "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r674" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-tables" ], "lang": { "en-us": { "role": { "label": "Intangible Asset and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of intangible asset and goodwill. Includes, but is not limited to, finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r863", "r866" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-8-segment-information", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-details-textual", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-schedule-of-segment-information-details", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-tables" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Table]", "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total." } } }, "auth_ref": [ "r174", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r199", "r200", "r201" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-8-segment-information-tables" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Table Text Block]", "documentation": "Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total." } } }, "auth_ref": [ "r847", "r849", "r850", "r851", "r852", "r853", "r854", "r856", "r857", "r860" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r366", "r368", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r402" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r6", "r7", "r31" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r35" ] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SecuredDebt", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details" ], "lang": { "en-us": { "role": { "label": "Term Loan", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r772", "r777", "r941", "r942", "r943", "r946" ] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SecuredDebtCurrent", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_SecuredDebtCurrent", "negatedLabel": "Less: current portion", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r775" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Security12bTitle", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r754" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SecurityExchangeName", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r756" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-8-segment-information" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Text Block]", "documentation": "The entire disclosure for segment reporting." } } }, "auth_ref": [ "r167", "r173", "r174", "r175", "r176", "r177", "r189", "r191", "r192", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r205", "r665", "r666", "r667", "r668", "r670", "r671", "r672" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Selling, general, and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r18", "r656", "r657", "r658", "r660", "r826" ] }, "nrc_SellingGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "SellingGeneralAndAdministrativeExpenseMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense [Member]", "documentation": "Represents the expense related to selling, general and administrative." } } }, "auth_ref": [] }, "nrc_ServiceBasedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "ServiceBasedStockOptionsMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Service based Stock Options [Member]", "documentation": "Represents the Service based Stock Options" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Non-cash share-based compensation expense", "terseLabel": "Noncash stock compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Expected dividend yield at date of grant", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r395" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Expected stock price volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r396" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r32", "r33" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, number (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r376" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, weighted average exercise price (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r376" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Expired, number (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r381" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "terseLabel": "Forfeited, number of options (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r380", "r769", "r779", "r780", "r893", "r894" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Granted, number of options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r378", "r769", "r779", "r780", "r893", "r894" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Outstanding, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Beginning balance, outstanding, number of options (in shares)", "periodEndLabel": "Outstanding, number (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r374", "r375" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Beginning balance, outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r374", "r375" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Exercised, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r379" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Granted, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r378" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r692" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Expected life of options (in years) (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r393" ] }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares)", "documentation": "Number of nonvested restricted shares outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, aggregate intrinsic value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r14" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Exercisable, weighted average remaining contractual term (Year)", "documentation": "Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r14" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Outstanding, weighted average contractual term (Year)", "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r34" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r117", "r118" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r52", "r53", "r60", "r88", "r89", "r99", "r100", "r101", "r125", "r126", "r127", "r131", "r139", "r141", "r143", "r168", "r209", "r212", "r252", "r253", "r255", "r305", "r318", "r323", "r324", "r325", "r328", "r330", "r332", "r356", "r357", "r361", "r362", "r405", "r423", "r424", "r435", "r436", "r437", "r440", "r448", "r449", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r473", "r474", "r475", "r476", "r485", "r491", "r492", "r493", "r494", "r495", "r496", "r499", "r507", "r520", "r526", "r527", "r534", "r535", "r543", "r553", "r567", "r568", "r569", "r585", "r633", "r900" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementLineItems", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-2-details-textual", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables", "http://nrchealth.com/20260331/role/statement-note-3-income-taxes", "http://nrchealth.com/20260331/role/statement-note-3-income-taxes-details-textual", "http://nrchealth.com/20260331/role/statement-note-4-notes-payable", "http://nrchealth.com/20260331/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-details-textual", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-details-textual", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-tables", "http://nrchealth.com/20260331/role/statement-note-8-segment-information", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-details-textual", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-schedule-of-segment-information-details", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-tables", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual", "http://nrchealth.com/20260331/role/statement-notes-4-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r60", "r61", "r64", "r65", "r71", "r81", "r83", "r86", "r87", "r88", "r89", "r91", "r125", "r126", "r127", "r168", "r307", "r308", "r310", "r312", "r316", "r318", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r331", "r332", "r336", "r499", "r523", "r526", "r527", "r533", "r534", "r535", "r581", "r586", "r587", "r590", "r591", "r592", "r593", "r594", "r595", "r597", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r633", "r653", "r659", "r660", "r747", "r990" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r54", "r60", "r61", "r64", "r65", "r71", "r81", "r83", "r86", "r87", "r88", "r89", "r91", "r125", "r126", "r127", "r168", "r206", "r307", "r308", "r310", "r312", "r316", "r318", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r331", "r332", "r336", "r499", "r523", "r526", "r527", "r533", "r534", "r535", "r543", "r581", "r586", "r587", "r590", "r591", "r592", "r593", "r594", "r595", "r597", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r633", "r653", "r659", "r660", "r747", "r990" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "lang": { "en-us": { "role": { "label": "Shares of common stock for the exercise of stock options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r379", "r769", "r779", "r780", "r892", "r893", "r894", "r896", "r897", "r941", "r942", "r944", "r945" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised", "terseLabel": "Issuance of shares of common stock for the exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r769", "r779", "r780", "r892", "r893", "r894", "r896", "r897", "r941", "r942", "r944", "r945" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r29", "r599", "r615", "r634", "r635", "r736", "r753", "r783", "r834", "r837", "r838", "r862", "r933", "r991" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 equity:" } } }, "auth_ref": [] }, "nrc_SubscriptionServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "SubscriptionServicesMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual" ], "lang": { "en-us": { "role": { "label": "Subscription Services [Member]", "documentation": "Represents information pertaining to subscription services." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r497", "r509" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTable", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r497", "r509" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r497", "r509" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event", "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r497", "r509" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-9-subsequent-event" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r508", "r510" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash paid for:" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TableTextBlock", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-tables", "http://nrchealth.com/20260331/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-tables", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-tables", "http://nrchealth.com/20260331/role/statement-note-8-segment-information-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r720", "r867", "r868", "r869", "r870", "r872", "r873", "r876", "r877" ] }, "nrc_The2006EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "The2006EquityIncentivePlanMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2006 Equity Incentive Plan [Member]", "documentation": "Represents the 2006 Equity Incentive plan." } } }, "auth_ref": [] }, "nrc_The2025OmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "The2025OmnibusIncentivePlanMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20260331/role/statement-note-5-sharebased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2025 Omnibus Incentive Plan [Member]", "documentation": "Relating to the 2025 Omnibus Incentive Plan." } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r351", "r681", "r688" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r351", "r681", "r688" ] }, "nrc_TradeNames1Member": { "xbrltype": "domainItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "TradeNames1Member", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Trade Names 1 [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TradeNamesMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20260331/role/statement-note-6-goodwill-and-other-intangible-assets" ], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r700", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r875", "r876", "r877" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r761" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "TradingSymbol", "presentation": [ "http://nrchealth.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TransferredOverTimeMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20260331/role/statement-note-2-contracts-with-customers-1-details-textual" ], "lang": { "en-us": { "role": { "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r681", "r682", "r688" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonMember", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r526", "r527", "r535", "r900" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonShares", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r334", "r335", "r941", "r942", "r945" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockSharesAcquired", "terseLabel": "Purchase of shares of treasury stock (in shares)", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r780", "r892", "r894", "r896", "r897", "r941", "r942", "r944", "r945" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, 9,329,252 and 7,989,028 Common shares in 2025 and 2024, respectively, at cost", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r898", "r899", "r900" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedTerseLabel": "Purchase of shares treasury stock", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r769", "r779", "r780", "r892", "r893", "r894", "r896", "r897" ] }, "nrc_TreasuryStockValueRepurchaseOfSharesForTreasuryInAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "TreasuryStockValueRepurchaseOfSharesForTreasuryInAccountsPayableAndAccruedExpenses", "crdr": "debit", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Repurchase of shares for treasury in accounts payable and accrued expenses", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased for treasury in accounts payable and accrued expenses during the period" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UseOfEstimates", "presentation": [ "http://nrchealth.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r42", "r43", "r169", "r170", "r171", "r172", "r539", "r541", "r662" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Diluted (in shares)", "totalLabel": "Denominator for diluted earnings per share \u2013 adjusted weighted average shares (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r148", "r161" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "lang": { "en-us": { "role": { "label": "Weighted average shares and share equivalents outstanding:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://nrchealth.com/20260331/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20260331/role/statement-note-7-earnings-per-share-net-income-per-share-computation-details" ], "lang": { "en-us": { "role": { "label": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding \u2013 basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r146", "r161" ] }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)" } } }, "auth_ref": [] }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "nrc_statement-statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "lang": { "en-us": { "role": { "label": "Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)" } } }, "auth_ref": [] }, "nrc_statement-statement-note-2-contracts-with-customers-tables": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-2-contracts-with-customers-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Contracts With Customers" } } }, "auth_ref": [] }, "nrc_statement-statement-note-4-notes-payable-tables": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-4-notes-payable-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Notes Payable" } } }, "auth_ref": [] }, "nrc_statement-statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "lang": { "en-us": { "role": { "label": "Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)" } } }, "auth_ref": [] }, "nrc_statement-statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details)" } } }, "auth_ref": [] }, "nrc_statement-statement-note-5-sharebased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-5-sharebased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Share-Based Compensation" } } }, "auth_ref": [] }, "nrc_statement-statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)" } } }, "auth_ref": [] }, "nrc_statement-statement-note-6-goodwill-and-other-intangible-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-6-goodwill-and-other-intangible-assets-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Other Intangible Assets" } } }, "auth_ref": [] }, "nrc_statement-statement-note-7-earnings-per-share-net-income-per-share-computation-details": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-7-earnings-per-share-net-income-per-share-computation-details", "lang": { "en-us": { "role": { "label": "Note 7 - Earnings Per Share - Net Income Per Share Computation (Details)" } } }, "auth_ref": [] }, "nrc_statement-statement-note-7-earnings-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-7-earnings-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Earnings Per Share" } } }, "auth_ref": [] }, "nrc_statement-statement-note-8-segment-information-schedule-of-segment-information-details": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-8-segment-information-schedule-of-segment-information-details", "lang": { "en-us": { "role": { "label": "Note 8 - Segment Information - Schedule of Segment Information (Details)" } } }, "auth_ref": [] }, "nrc_statement-statement-note-8-segment-information-tables": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-note-8-segment-information-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Segment Information" } } }, "auth_ref": [] }, "nrc_statement-statement-notes-4-notes-payable-summary-of-notes-payable-details": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-notes-4-notes-payable-summary-of-notes-payable-details", "lang": { "en-us": { "role": { "label": "Notes 4 - Notes Payable - Summary of Notes Payable (Details)" } } }, "auth_ref": [] }, "nrc_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://nrchealth.com/20260331", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.Z.5.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-6" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-6" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 5.Q.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481108/505-30-30-6" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "805", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r763": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "340", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-2" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481108/505-30-30-6" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2C" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2D" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-16" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" } } } ZIP 60 0001437749-26-015083-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-26-015083-xbrl.zip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end XML 61 nrc20260331_10q_htm.xml IDEA: XBRL DOCUMENT 0000070487 2026-01-01 2026-03-31 0000070487 us-gaap:SubsequentEventMember 2026-04-27 2026-04-27 0000070487 2025-01-01 2025-03-31 0000070487 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0000070487 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0000070487 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0000070487 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0000070487 2025-12-31 0000070487 2026-03-31 0000070487 us-gaap:TradeNamesMember 2025-12-31 0000070487 us-gaap:TradeNamesMember 2026-03-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2025-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2026-03-31 0000070487 us-gaap:CustomerRelationshipsMember 2025-12-31 0000070487 us-gaap:CustomerRelationshipsMember 2026-03-31 0000070487 nrc:TradeNames1Member 2025-12-31 0000070487 nrc:TradeNames1Member 2026-03-31 0000070487 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0000070487 nrc:NonvestedMember 2025-01-01 2025-03-31 0000070487 nrc:NonvestedMember 2026-01-01 2026-03-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2026-01-01 2026-03-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2026-03-31 0000070487 nrc:NonvestedMember 2026-03-31 0000070487 us-gaap:EmployeeStockOptionMember 2026-03-31 0000070487 nrc:PerformanceBasedStockOptionsMember 2026-01-01 2026-03-31 0000070487 nrc:ServiceBasedStockOptionsMember 2026-03-31 0000070487 nrc:ServiceBasedStockOptionsMember 2026-01-01 2026-03-31 0000070487 nrc:ServiceBasedStockOptionsMember 2025-12-31 0000070487 nrc:ServiceBasedStockOptionsMember 2025-01-01 2025-03-31 0000070487 srt:MinimumMember nrc:ServiceBasedStockOptionsMember 2026-01-01 2026-03-31 0000070487 nrc:The2025OmnibusIncentivePlanMember 2026-03-31 0000070487 us-gaap:DelayedDrawTermLoanMember 2025-12-31 0000070487 us-gaap:DelayedDrawTermLoanMember 2026-03-31 0000070487 us-gaap:LongTermContractWithCustomerMember 2026-04-01 2026-03-31 0000070487 us-gaap:LongTermContractWithCustomerMember 2026-03-31 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-03-31 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-03-31 0000070487 nrc:SellingGeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0000070487 nrc:SellingGeneralAndAdministrativeExpenseMember 2026-01-01 2026-03-31 0000070487 nrc:DirectExpensesMember 2025-01-01 2025-03-31 0000070487 nrc:DirectExpensesMember 2026-01-01 2026-03-31 0000070487 srt:MaximumMember 2026-03-31 0000070487 srt:MinimumMember 2026-03-31 0000070487 2025-03-31 0000070487 2024-12-31 0000070487 us-gaap:TreasuryStockCommonMember 2025-03-31 0000070487 us-gaap:RetainedEarningsMember 2025-03-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000070487 us-gaap:CommonStockMember 2025-03-31 0000070487 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000070487 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000070487 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000070487 us-gaap:TreasuryStockCommonMember 2024-12-31 0000070487 us-gaap:RetainedEarningsMember 2024-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000070487 us-gaap:CommonStockMember 2024-12-31 0000070487 us-gaap:TreasuryStockCommonMember 2026-03-31 0000070487 us-gaap:RetainedEarningsMember 2026-03-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000070487 us-gaap:CommonStockMember 2026-03-31 0000070487 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0000070487 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000070487 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000070487 us-gaap:TreasuryStockCommonMember 2025-12-31 0000070487 us-gaap:RetainedEarningsMember 2025-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000070487 us-gaap:CommonStockMember 2025-12-31 0000070487 2026-04-30 iso4217:USD pure iso4217:USD shares shares Q1 2026 --12-31 false 0000070487 false false false false 1 1 0 0 0 0 0 0 P6Y P5Y P5Y P3Y 0 0 0 0 10-Q true 2026-03-31 false 001-35929 NRC Health DE 47-0634000 1245 Q Street Lincoln NE 68508 402 475-2525 Common Stock, $.001 par value NRC NASDAQ Yes Yes Accelerated Filer false false false 22536696 2547000 4139000 90000 80000 10833000 11108000 5662000 3914000 481000 528000 461000 520000 19984000 20209000 40305000 40474000 2165000 2227000 66152000 66152000 3123000 2498000 2830000 3318000 134559000 134878000 4015000 4014000 2227000 1169000 6603000 7218000 2582000 2897000 3606000 3625000 17192000 16201000 1768000 550000 477000 946000 38470000 36620000 74017000 75021000 5999000 5984000 2578000 3263000 121064000 120888000 0.01 0.01 2000000 2000000 0.001 0.001 110000000 110000000 31975649 31966504 22536696 22637252 32000 32000 185627000 183880000 -17682000 -17298000 9438953 9329252 154482000 152624000 13495000 13990000 134559000 134878000 34803000 33551000 13646000 13057000 13419000 10356000 2169000 1542000 29234000 24955000 5569000 8596000 35000 19000 1255000 899000 30000 7000 -1190000 -873000 4379000 7723000 1157000 1936000 3222000 5787000 0.14 0.25 0.14 0.25 21799000 22972000 21911000 22974000 32000 183880000 -17298000 -152624000 13990000 109701 -0 -0 -0 1858000 1858000 9145 0 139000 0 0 139000 0 1608000 0 0 1608000 0.16 -0 -0 3606000 -0 3606000 0 0 3222000 0 3222000 32000 185627000 -17682000 -154482000 13495000 31000 180249000 -17064000 -131932000 31284000 307709 -0 -0 -0 4967000 4967000 10014 0 132000 0 0 132000 0 171000 0 0 171000 0.12 -0 -0 2735000 -0 2735000 0 0 5787000 0 5787000 31000 180552000 -14012000 -136899000 29672000 3222000 5787000 2169000 1542000 -36000 1860000 -56000 76000 1608000 171000 0 31000 -0 -67000 27000 15000 -275000 272000 1627000 2419000 625000 -24000 30000 26000 942000 627000 -889000 -472000 1265000 -80000 935000 -285000 7180000 6646000 1834000 2986000 -1834000 -2986000 0 27738000 1030000 28724000 2500000 8000000 2500000 4503000 -0 62000 3000 2000 139000 132000 484000 280000 1935000 4920000 3625000 2770000 -6938000 -5391000 -1592000 -1731000 4139000 4233000 2547000 2502000 1247000 774000 80000 0 26000 450000 2131000 151000 47000 0 81000 0 34396000 0 62076000 0 351000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> (1) </td> <td style="width: auto;"> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </td> </tr> </tbody></table> Basis of Presentation Our condensed consolidated balance sheet at December 31, 2025, was derived from our audited consolidated balance sheet as of that date. All other financial statements contained herein are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) that we consider necessary for a fair presentation of financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States. Information and footnote disclosures included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in our Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2026. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Deferred Contract Costs We defer incremental costs of obtaining customer contracts. These costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. We deferred incremental costs of obtaining a contract of $908,000 and $354,000 in the three-month periods ended March 31, 2026, and 2025, respectively. Deferred contract costs, net of accumulated amortization was $3.1 million and $2.5 million at March 31, 2026, and December 31, 2025, respectively. Total amortization by expense classification for the three-month periods ended March 31, 2026, and 2025 was as follows (in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 27pt;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Direct expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Selling, general, and administrative expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">240</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">356</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">272</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">376</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> Fair Value Measurements Our contingent consideration liability was measured at fair value on a recurring basis using significant unobservable inputs (Level 3). The measurement period for the contingent consideration arrangement was completed as of December 31, 2025. The remaining liability was settled during the quarter and no balance remained at March 31, 2026. Commitments and Contingencies There were no material changes to the Company’s commitments, contingencies, or legal proceedings from those disclosed in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025. Recently Adopted Accounting Standards We elected the practical expedient under ASU 2025-05 to estimate expected credit losses for current accounts receivable and current contract assets by assuming current conditions as of the balance-sheet date remain unchanged over the remaining life of the assets. The adoption and election did not have a material impact on our condensed consolidated financial statements or related disclosures. Recent Accounting Pronouncements Not Yet Adopted We monitor recently issued accounting pronouncements to assess their potential impact on our consolidated financial statements and related disclosures. The following Accounting Standards Updates (“ASUs”) have been issued but not yet adopted. The Company has evaluated or is currently evaluating each standard to determine the impact of adoption. In February 2024, the FASB issued ASU 2024-03, which provides improvements to the disclosure requirements for expenses. The update primarily impacts disclosures by requiring entities to provide additional detail about the natural classification of significant expenses that are included in relevant income statement line items. ASU 2024-03 is effective for the Company for annual reporting periods beginning after December 15, 2026, and interim periods thereafter. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial position or results of operations, but it will result in expanded expense disclosures beginning with the Company’s annual financial statements for the year ending December 31, 2027. In September 2025, the FASB issued ASU 2025-06, which provides targeted improvements to the accounting for internal-use software. The update replaces the current project stage model with a principles-based framework and requires capitalization to begin when management authorizes and commits funding, and project completion is probable. ASU 2025-06 is effective for the Company for annual reporting periods beginning after December 15, 2027, including interim periods within those years. The Company is currently evaluating the effect of adopting this standard, and the impact is not yet known or reasonably estimable. The Company will determine the transition method for adoption and does not plan to adopt before the effective date. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Deferred Contract Costs We defer incremental costs of obtaining customer contracts. These costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. We deferred incremental costs of obtaining a contract of $908,000 and $354,000 in the three-month periods ended March 31, 2026, and 2025, respectively. Deferred contract costs, net of accumulated amortization was $3.1 million and $2.5 million at March 31, 2026, and December 31, 2025, respectively. Total amortization by expense classification for the three-month periods ended March 31, 2026, and 2025 was as follows (in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 27pt;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Direct expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Selling, general, and administrative expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">240</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">356</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">272</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">376</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 908000 354000 3100000 2500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 27pt;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Direct expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Selling, general, and administrative expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">240</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">356</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">272</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">376</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 32000 20000 240000 356000 272000 376000 Fair Value Measurements Our contingent consideration liability was measured at fair value on a recurring basis using significant unobservable inputs (Level 3). The measurement period for the contingent consideration arrangement was completed as of December 31, 2025. The remaining liability was settled during the quarter and no balance remained at March 31, 2026. Commitments and Contingencies There were no material changes to the Company’s commitments, contingencies, or legal proceedings from those disclosed in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025. Recently Adopted Accounting Standards We elected the practical expedient under ASU 2025-05 to estimate expected credit losses for current accounts receivable and current contract assets by assuming current conditions as of the balance-sheet date remain unchanged over the remaining life of the assets. The adoption and election did not have a material impact on our condensed consolidated financial statements or related disclosures. Recent Accounting Pronouncements Not Yet Adopted We monitor recently issued accounting pronouncements to assess their potential impact on our consolidated financial statements and related disclosures. The following Accounting Standards Updates (“ASUs”) have been issued but not yet adopted. The Company has evaluated or is currently evaluating each standard to determine the impact of adoption. In February 2024, the FASB issued ASU 2024-03, which provides improvements to the disclosure requirements for expenses. The update primarily impacts disclosures by requiring entities to provide additional detail about the natural classification of significant expenses that are included in relevant income statement line items. ASU 2024-03 is effective for the Company for annual reporting periods beginning after December 15, 2026, and interim periods thereafter. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial position or results of operations, but it will result in expanded expense disclosures beginning with the Company’s annual financial statements for the year ending December 31, 2027. In September 2025, the FASB issued ASU 2025-06, which provides targeted improvements to the accounting for internal-use software. The update replaces the current project stage model with a principles-based framework and requires capitalization to begin when management authorizes and commits funding, and project completion is probable. ASU 2025-06 is effective for the Company for annual reporting periods beginning after December 15, 2027, including interim periods within those years. The Company is currently evaluating the effect of adopting this standard, and the impact is not yet known or reasonably estimable. The Company will determine the transition method for adoption and does not plan to adopt before the effective date. <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> (2) </td> <td style="width: auto;"> CONTRACTS WITH CUSTOMERS </td> </tr> </tbody></table> We derive a majority of our revenue from renewable subscription‑based service agreements with our customers. These arrangements represent a single promise to stand ready to provide services over the contractual term and are recognized ratably as the related services are provided. As a result, the significant majority of our revenue is recognized over time. Revenue recognized over time totaled $33.3 million and $31.0 million for the three months ended March 31, 2026 and 2025, respectively. Revenue associated with performance obligations satisfied at a point in time, including one‑time specified services, as well as revenue from fixed, non‑subscription and unit‑priced service arrangements, was not material for either period. Total revenue for the three months ended March 31, 2026, was $34.8 million, compared to $33.6 million for the three months ended March 31, 2025, with the increase primarily attributable to growth in subscription‑based services. Our revenue recognition patterns during the quarter are consistent with those disclosed in our Annual Report on Form 10‑K. The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Trade accounts receivables </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,833</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,108</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Contract assets included in other current assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">132</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Deferred revenue, current portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,192</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,201</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Noncurrent deferred revenue included in other long-term liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">74</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> Deferred revenue increased by $1.0 million primarily due to new billings exceeding revenue recognized during the period. We have elected to apply the practical expedient to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Total remaining contract revenue for contracts with original duration of greater than one year expected to be recognized in the future related to performance obligations that are unsatisfied at March 31, 2026, approximated $194.5 million, of which $61.5 million is expected to be recognized over the next 12 months, with the remainder recognized thereafter. 33300000 31000000 34800000 33600000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Trade accounts receivables </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,833</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,108</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Contract assets included in other current assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">132</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Deferred revenue, current portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,192</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,201</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Noncurrent deferred revenue included in other long-term liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">74</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 10833000 11108000 75000 132000 17192000 16201000 18000 74000 1000000 194500000 61500000 P12M <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> (3) </td> <td style="width: auto;"> INCOME TAXES </td> </tr> </tbody></table> The effective tax rate was 26% and 25% for the three-month periods ended March 31, 2026, and 2025, respectively. The increase in the effective tax rate was primarily driven by a higher impact from non-deductible executive compensation under IRC Section 162(m). 0.26 0.25 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> (4) </td> <td style="width: auto;"> NOTES PAYABLE </td> </tr> </tbody></table> Our long‑term debt consists of amounts outstanding under the Credit Agreement entered into in February 2025, as described in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025. There were no amendments, modifications, or new debt issuances during the three months ended March 31, 2026. Our long-term debt consists of the following (in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Delayed Draw Term Loan </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">78,376</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79,406</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: current portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(4,015</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(4,014</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: unamortized debt issuance costs </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(344</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(371</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Notes payable, net of current portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">74,017</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,021</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> As of March 31, 2026, we were in compliance with all financial covenants. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Delayed Draw Term Loan </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">78,376</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">79,406</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: current portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(4,015</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(4,014</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: unamortized debt issuance costs </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(344</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(371</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Notes payable, net of current portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">74,017</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,021</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 78376000 79406000 4015000 4014000 344000 371000 74017000 75021000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> (5) </td> <td style="width: auto;"> SHARE-BASED COMPENSATION </td> </tr> </tbody></table> Our 2025 Omnibus Incentive Plan (the “2025 Omnibus Incentive Plan”), which became effective on May 7, 2025, provides for the granting of equity-based awards, as described in our Annual Report on Form 10-K for the year ended December 31, 2025. At March 31, 2026, 3.9 million shares of common stock were available for issuance pursuant to future grants under the plan. Service-Based Stock Option Awards We grant stock options to directors and select executives with vesting based on specified service periods. Vesting terms vary with each grant and option awards are generally five to ten years following the date of grant. We recognize compensation expense on a straight-line basis over the service period specified in the award. We granted 17,638 and 11,021 service-based stock option awards during the three-month period ended March 31, 2026 and 2025, respectively. The fair value of service-based stock options granted in 2026 was estimated using a Black-Scholes valuation model with the following weighted average assumptions: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 84%;"> Expected dividend yield at date of grant </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.49</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected stock price volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34.51</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected life of options (in years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes. The following table summarizes service-based stock option activity for the three-month period ended March 31, 2026: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Options </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Terms (Years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value (In thousands) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Outstanding at December 31, 2025 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">608,782</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27.52</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,638</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22.01</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,145</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15.23</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expired </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Forfeited </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding at March 31, 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">617,275</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27.54</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.05</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercisable at March 31, 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">401,138</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33.13</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.17</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> Performance-Based Stock Option Awards We also grant stock options to selected executives with vesting contingent upon meeting certain Company-wide performance goals. The performance goals for options issued in 2024 are based on reaching a total recurring contract value target, measured at the end of the performance period, December 31, 2026. Vesting is also dependent upon remaining in our employment through the performance period. The performance awards issued in 2024 have a six-year contractual term. We recognize compensation expense prospectively from the date it is deemed probable that the performance goal will be met through the end of the performance period. We did not recognize compensation expense related to performance-based awards in 2025 or 2026 since achieving the performance goals was not deemed probable. There was no activity related to performance‑based stock option awards during the three months ended March 31, 2026. As of March 31, 2026, the total unrecognized compensation cost related to non-vested performance-based and service-based stock option awards was approximately $1.4 million which was expected to be recognized over a weighted average period of 1.6 years. There was $139,000 and $132,000 of cash received from stock options exercised during the three-month periods ended March 31, 2026 and 2025, respectively. We recognized $245,000 and $171,000 of non-cash compensation expense for the three-month periods ended March 31, 2026, and 2025, respectively, which is included in selling, general, and administrative expenses. Non-vested Stock Awards and Restricted Stock Units No shares of non-vested restricted stock awards (RSAs) were granted during the three-month periods ended March 31, 2026 and 2025. At March 31, 2026 and December 31, 2025, there were 829,000 non-vested restricted stock awards outstanding with total remaining unrecognized compensation expense of $7.7 million expected to be recognized over a weighted average period of 2.1 years. We recognized non-cash compensation expense of $1.0 million for the three-month period ended March 31, 2026, related to non-vested stock, which is included in selling, general, and administrative expenses. No expense was recognized for the three-month period ended March 31, 2025. We granted 160,000 restricted stock units (RSUs) during the three months ended March 31, 2026. No RSUs were granted in 2025. RSUs do not carry dividend or voting rights prior to vesting. At March 31, 2026, 160,000 RSUs were outstanding, with total remaining unrecognized compensation expense of $2.4 million expected to be recognized over a weighted‑average period of 1.8 years. We recognized non‑cash compensation expense of $331,000 for the three months ended March 31, 2026, related to RSUs, which is included in selling, general, and administrative expenses. No expense was recognized for the three-month period ended March 31, 2025. 3900000 17638 11021 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 84%;"> Expected dividend yield at date of grant </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.49</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected stock price volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34.51</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected life of options (in years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 0.0349 0.3451 0.0385 P5Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Options </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Terms (Years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value (In thousands) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Outstanding at December 31, 2025 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">608,782</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27.52</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,638</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22.01</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,145</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15.23</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expired </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Forfeited </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding at March 31, 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">617,275</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27.54</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.05</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercisable at March 31, 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">401,138</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33.13</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.17</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 608782 27.52 17638 22.01 9145 15.23 0 0 617275 27.54 P7Y18D 0 401138 33.13 P6Y2M1D 0 1400000 P1Y7M6D 139000 132000 245000 171000 829000 829000 7700000 P2Y1M6D 1000000 160000 160000 2400000 P1Y9M18D 331000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> (6) </td> <td style="width: auto;"> GOODWILL AND OTHER INTANGIBLE ASSETS </td> </tr> </tbody></table> The carrying amount of goodwill totaled $66,152 at March 31, 2026, and no impairments were recognized during the three month-period then ended. Intangible assets consisted of the following (in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Non-amortizing intangible assets: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Indefinite trade name </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Amortizing intangible assets: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Customer related </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,772</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,772</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Technology </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,790</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,790</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Trade names </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total amortizing intangible assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accumulated amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,160</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,098</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other intangible assets, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,165</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,227</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 66152000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Non-amortizing intangible assets: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Indefinite trade name </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Amortizing intangible assets: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Customer related </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,772</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,772</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Technology </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,790</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,790</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Trade names </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total amortizing intangible assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accumulated amortization </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,160</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(13,098</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other intangible assets, net </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,165</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,227</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 1191000 1191000 9772000 9772000 2790000 2790000 1572000 1572000 14134000 14134000 13160000 13098000 2165000 2227000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> (7) </td> <td style="width: auto;"> EARNINGS PER SHARE </td> </tr> </tbody></table> Basic net income per share was computed using the weighted-average shares of common stock outstanding during the period. Diluted net income per share was computed using the weighted-average shares of common stock and, if dilutive, the potential common stock outstanding during the period. Potential shares of common stock consist of the incremental common stock issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options and restricted stock units is reflected in diluted earnings per share by application of the treasury stock method. We had 370,699 and 427,838 options of common stock for the three-month periods ended March 31, 2026, and 2025, respectively, which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive. Performance-based stock option awards have not been included in the computation since the conditions have not been met. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the Three Months Ended March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the Three Months Ended March 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (In thousands, except per share data) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Numerator for net income per share – basic: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,222</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,787</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Allocation of distributed and undistributed income to unvested restricted stock shareholders </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(133</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income attributable to common shareholders </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,089</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,787</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Denominator for net income per share – basic: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average shares of common stock outstanding – basic </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,799</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,972</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income per share – basic </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Numerator for net income per share – diluted: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income attributable to common shareholders for basic computation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,089</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,787</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Denominator for net income per share – diluted: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average shares of common stock outstanding – basic </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21,799</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22,972</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average effect of dilutive securities – stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">56</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average effect of dilutive securities – restricted stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Denominator for diluted earnings per share – adjusted weighted average shares </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,911</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,974</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income per share – diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 370699 427838 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the Three Months Ended March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the Three Months Ended March 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (In thousands, except per share data) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Numerator for net income per share – basic: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,222</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,787</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Allocation of distributed and undistributed income to unvested restricted stock shareholders </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(133</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income attributable to common shareholders </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,089</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,787</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Denominator for net income per share – basic: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average shares of common stock outstanding – basic </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,799</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,972</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income per share – basic </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Numerator for net income per share – diluted: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income attributable to common shareholders for basic computation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,089</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,787</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Denominator for net income per share – diluted: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average shares of common stock outstanding – basic </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21,799</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22,972</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average effect of dilutive securities – stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">56</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average effect of dilutive securities – restricted stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Denominator for diluted earnings per share – adjusted weighted average shares </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,911</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,974</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income per share – diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.14</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 3222000 5787000 133000 -0 3089000 5787000 21799000 22972000 0.14 0.25 3089000 5787000 21799000 22972000 56000 2000 56000 0 21911000 22974000 0.14 0.25 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> (8) </td> <td style="width: auto;"> Segment Information </td> </tr> </tbody></table> The Company assesses segment reporting in accordance with ASC 280, Segment Reporting. Based on how the business is managed and the financial information reviewed by our Chief Operating Decision Maker (“CODM”), who is our Chief Executive Officer, the Company operates as one operating segment and one reportable segment. The CODM evaluates the Company’s performance and allocates resources based on consolidated net income, which is the primary measure used to assess results against forecasts and historical trends. Because the Company has a single operating segment, our segment results are identical to the amounts presented in our Consolidated Statements of Income, and we have no inter‑segment revenues or transfers. In addition to consolidated net income, the CODM is regularly provided supplemental information regarding certain management bonuses (when applicable), noncash stock compensation expense, and the related income tax, as presented below for the three months ending (in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Noncash stock compensation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,608</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">171</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Tax benefit on noncash stock compensation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">262</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2026 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> Noncash stock compensation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,608</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">171</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Tax benefit on noncash stock compensation </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">262</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 1608000 171000 262000 43000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 45pt;"> (9) </td> <td style="width: auto;"> Subsequent Event </td> </tr> </tbody></table> On April 27, 2026, the Compensation and Talent Committee of our Board of Directors approved amendments to equity awards granted to certain executives in 2025. The amendments eliminated the Company’s right to repurchase the shares underlying these awards if the executives’ employment terminated under certain circumstances prior to the third anniversary of the respective grant dates. The impacted executives were also awarded bonuses intended to cover their anticipated tax obligations in connection with these amendments. The amendments and related bonuses are expected to result in approximately $9.4 million of expense during the second quarter of 2026, consisting of (i) approximately $6.5 million of non-cash accelerated equity compensation expense, substantially all of which would otherwise have been recognized ratably through the second quarter of 2028, and (ii) approximately $2.9 million of cash bonus expense, primarily related to tax payments. The Company’s effective tax rate for the second quarter and the remainder of 2026 is expected to be impacted by the non-deductibility of these amounts. 9400000 6500000 2900000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 63pt;"> <a href="#" id="item5"></a>ITEM 5. </td> <td style="width: auto;"> Other Information </td> </tr> </tbody></table> During the first quarter of 2026, no director or officer adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.